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Objectives 
 
To generate data from selected in vivo genotoxicity tests, and to assess the correlation between in 
vivo and in vitro results taking into account the kinetic results. 
 
Schedule 
 
The WP6 lasted for 16 months from October 2011 until the end of the Joint Action (February 2013). 
Few months at the beginning were devoted to trainings and trials before performing the experiments 
on Manufactured Nanomaterials (MNs). Even though, some last results are not yet available and will 
be collected after the end of the Joint Action, especially on the micronucleus on colon as well as on 
histology. 
 
Methodology 
 
This workpackage investigated the genotoxicity of MNs. For this purpose, 3 complementary tests 
were performed on rodents: 
- Comet assay (early DNA damage) 
- Micronucleus assay (chromosome and genome mutations) 
- Mutation Lac Z assay (gene mutations). 
From an ethical point of view, the genotoxicity tests were deliberately combined in the same 
animal in order to reduce the number of animals. Therefore, comet and micronucleus tests were 
performed concomitantly for all the MNs. Similarly, during the mutation LacZ assay, samples for 
comet and micronucleus assays were also collected. 
Moreover, other endpoints, concerning inflammation and oxidative stress which have been reported 
to be involved in MNs toxicity, were also measured:  
- Broncho alveolar cells count for intratracheal instillation 
- Histology (mainly if a positive response with the comet assay was detected) 
- Modified comet assay with FpG enzyme for selective detection of oxidative lesions as 
well as lipid peroxidation product malondialdehyde (MDA) in plasma. 
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Except the mutation LacZ assay which was performed on mice, all the experiments were performed 
on rats, this species being the main model for toxicological studies. As no indication was available on 
the gender sensitivity, males (Sprague Dawley or Wistar strains) were chosen as recommended by 
EFSA (2012) for the in vivo comet assay. Several groups of animals were distinguished with 4 to 5 
animals per group: vehicle control, positive control and 3 treated groups (3 doses of MNs). Two 
routes were principally investigated as representing the main routes of human exposure: 
intratracheal instillation and gavage. The MNs were administered 3 days in a row at 24h interval and 
with samples collection 3 to 6 h after the last administration in order to increase the sensitivity and 
according to the recommendations of EFSA (2012) on the in vivo comet assay. Several organs/tissues 
were collected both from the site of contact and systemic organs (Figure 1). 
For the comet assay, at least 5 organs were investigated among intestine, colon, blood, liver, spleen, 
kidney and bone marrow for gavage experiment and among bronchoalveolar fluid, lung, blood, liver, 
spleen, kidney and bone marrow for intratracheal exposure. In most cases, the FpG modified comet 
assay was also performed. 
Bone marrow and colon were also used for micronucleus assay. On bone marrow, the assay was 
conducted according to the OECD guideline n°474. 
Pieces of organs for histology could have also been collected within the same experiment. 
 
 
Figure 1: Schematic overview of the genotoxicity tests performed and the organs investigated 
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The Lac Z mutation assay was performed on mice (C57BI6/J strain). Only two iv (intravenous) 
administrations at 24h interval were done as some toxicity on the site of injection had been observed 
in a preliminary trial, after the 3rd injection. Following a fixation period of 28 days after MN exposure, 
the mutation rate in selected organs was measured. Liver and spleen were investigated as they show 
some accumulation of TiO2. Complementary genotoxic assays were done concomitantly: comet 
assay on the selected organs and micronucleus assay in peripheral blood reticulocytes (Figure 2). 
 
Figure 2: Schematic overview of the Lac Z assay with NM102 and the genotoxic endpoints 
investigated 
 
Training 
 
Training was necessary for the colon micronucleus assay as only one laboratory out of the three 
involved in this part of the workpackage had already used this assay for other projects during the last 
5 years. Few days training were done in September 2011 in one of the two laboratories. However, 
since face to face training was not possible for the other laboratory, the most experienced laboratory 
provided English translation of the protocol, explanations and a video in order to promote the set up 
of this technique in the last laboratory.  
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Trials 
 
1) Micronucleus on bone marrow 
Trials for the bone marrow micronucleus assay were planned before the experiments with MNs as 
the work for scoring was shared between several laboratories. In most cases, the laboratory 
performing the comet assay scored the comet slides and sent the micronucleus bone marrow slides 
to another laboratory in charge of their scoring. Some slides exchanges were therefore settled 
between the laboratories so as the quality of the slides provided by the collecting laboratory was 
correct for the scoring lab. 
 
2) Positive controls chemical and nanosized 
Two chemical positive controls were tested: MethylMethaneSulfonate (MMS) and 
Cyclophosphamide (CPA). They were both administered by gavage according to the schedule of 
administration (3 administrations, 24h interval and tissue collection after 3 to 6h of the last 
administration). The results are summarized in the Table 1. 
 
The Carbon Black (CB) Printex® 90 was selected for investigating its use as a nanosized positive 
control. Both oral and intratracheal studies were conducted and the main results are presented in 
the Table 1.  
 
Table 1: Results of the comet and micronucleus assays (MNA) following gavage of various 
investigated compound as positive controls (MMS, CPA and CB) 
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Set up of protocols 
 
 
Rodents were bred, maintained, treated and sacrificed according to European Union 
directives.   
An effort was made within this workpackage to reduce the number of animals used in each 
experiment, by integrating multiple endpoints and analyzing several organs concomitantly in the 
same animal. 
1) Positive controls 
1.1 Chemical 
According to the results obtained during the trials, the MMS was selected as the chemical positive 
control. It was given by gavage for both routes (oral and intratracheal) but with a different dose. 
For oral administration, it was recommended to give 100 mg/kg 2 days at 24h interval and then 80 
mg/kg for the last administration to be sure that it will induce micronuclei formation in the colon. 
However, for intratracheal route, it was recommended to use 50 mg/kg 48 h before tissue collection 
and then 25 mg/kg 24 and 3 h before animal necropsy as this dose was enough to induce micronuclei 
formation in the bone marrow. CPA has been used also as positive chemical for the micronucleus 
assay in certain laboratories due to historical controls. 
However, one laboratory has also added EthylNitrosoUrea (ENU) as a second chemical positive 
control for blood and bone marrow. 
 
1.2 Nanosized 
A genotoxic positive response with CB was only observed on few organs following gavage or 
intratracheal exposure (table 1). Moreover, some results were inconsistent from laboratory to 
laboratory and the addition of this compound was not compulsory for in vivo experiments. 
 
2) Comet assay  
 
The comet assay protocol was not harmonized due to the lack of time available for performing those 
experiments. Therefore, each laboratory used their own protocol both for cell isolation (Tables 2 & 3) 
and for the technical conditions (V/cm, % agarose, time of unwinding, electrophoresis, FpG 
concentration and time of incubation, etc). 
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Table 2. Methods used for cell preparation for the in vivo comet assay after instillation with 
Nanogenotox MNs. (NP = No Specific Preparation; ND = Not done) 
Tissue BAL fluid Lung 
Blood 
(not 
compulsory) 
Bone 
marrow 
 
Spleen Liver Kidney 
TiO2             
NM-102 Lavage 
Freezing+ 
mechanical 
ND ND Freezing+ 
mechanical 
Freezing+ 
mechanical 
Freezing+ 
mechanical 
NM-103 Lavage 
Freezing+ 
mechanical 
ND ND Freezing+ 
mechanical 
Freezing+ 
mechanical 
Freezing+ 
mechanical 
NM-104 Lavage 
Freezing+ 
mechanical 
ND ND Freezing+ 
mechanical 
Freezing+ 
mechanical 
Freezing+ 
mechanical 
NM-105 Lavage 
Freezing+ 
mechanical 
ND ND Freezing+ 
mechanical 
Freezing+ 
mechanical 
Freezing+ 
mechanical 
SiO2     
   
NM-200 Lavage Enzymatic NP Flushing Mechanical Enzymatic Enzymatic 
NM-201 Lavage Enzymatic 
NP Flushing Mechanical Enzymatic Enzymatic 
NM-202 Lavage Enzymatic 
NP Flushing Mechanical Enzymatic Enzymatic 
NM-203 Lavage Enzymatic NP Flushing Mechanical Enzymatic Enzymatic 
MWCNT     
   
NM-400 
ND Mechanical ND ND Open in liquid Mechanical Mechanical 
NM-401 Lavage Mechanical 
ND ND Open in liquid Open in liquid Mechanical 
NM-402 Lavage 
Mechanical ND ND Open in liquid Open in liquid Mechanical 
NRCWE-006 Lavage Mechanical ND ND Open in liquid Open in liquid Mechanical 
 
Table 3. Methods used for cell preparation for the in vivo comet assay after gavage with 
Nanogenotox MNs. (NP = No Specific Preparation; ND = Not done) 
Tissue Intestine Colon 
Blood 
(not 
compulsory) 
Bone 
marrow 
 
Spleen Liver Kidney 
TiO2              
NM-102 
Scrapping  + 
freezing 
Scrapping + 
freezing 
Lymphocytes 
isolation 
Flushing + 
freezing 
Freezing + Open 
in liquid, 
mechanical 
Freezing 
+Chopping in 
liquid, enzymatic 
Freezing 
+Chopping in 
liquid, enzymatic 
NM-103 
Scrapping + 
freezing 
Scrapping + 
freezing 
Lymphocytes 
isolation 
Flushing + 
freezing 
Freezing + Open 
in liquid, 
mechanical 
Freezing 
+Chopping in 
liquid, enzymatic 
Freezing 
+Chopping in 
liquid, enzymatic 
NM-104 
Scrapping + 
freezing 
Scrapping + 
freezing 
Lymphocytes 
isolation 
Flushing + 
freezing 
Freezing + Open 
in liquid, 
mechanical 
Freezing 
+Chopping in 
liquid, enzymatic 
Freezing 
+Chopping in 
liquid, enzymatic 
NM-105 
Scrapping + 
freezing 
Scrapping + 
freezing 
Lymphocytes 
isolation 
Flushing + 
freezing 
Freezing + Open 
in liquid, 
mechanical 
Freezing 
+Chopping in 
liquid, enzymatic 
Freezing 
+Chopping in 
liquid, enzymatic 
SiO2     
   
NM-200 Scrapping Scrapping NP Flushing Flushing Mechanical Mechanical 
NM-201 Scrapping Scrapping 
NP Flushing Flushing Mechanical Mechanical 
NM-202 Scrapping Scrapping NP Flushing Flushing Mechanical Mechanical 
NM-203 Scrapping Scrapping NP Flushing Flushing Mechanical Mechanical 
MWCNT        
NM-400 
ND Scrapping ND ND Open in liquid Mechanical Mechanical 
NM-401 
ND Scrapping + 
enzymatic 
ND ND Open in liquid Open in liquid Mechanical 
NM-402 
ND Scrapping + 
enzymatic 
ND ND Open in liquid Open in liquid Mechanical 
NRCWE-006 
ND Scrapping + 
enzymatic 
ND ND Open in liquid Open in liquid Mechanical 
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3) Micronucleus assays 
- On bone marrow, according to the OECD guideline n°474; staining was done whether by 
Giemsa or by acridine orange 
- On paraffin sections of swiss-rolled colon; DNA staining was done with Feulgen and 
counterstaining with Brilliant Green. 
 
Statistics 
 
 
1) Comet assay and LacZ mutation assay 
 
The unit for statistical analysis was the animal. For comet values, the Kruskal-Wallis test was first 
performed. If a positive result was obtained, the Mann-Whitney test with a Bonferroni correction 
was done in order to know whether data from exposed animals were significantly different from the 
control. For MMS and ENU, the Mann-Whitney test was used. 
 
2) Micronucleus assays 
 
For bone marrow, blood and colon assays, the chi-square test was done. 
 
3) Cytological and biochemical parameters 
 
Data were log-transformed and an ANOVA followed by a Dunnett test was performed. 
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Methods and results 
 
1) TiO2 
Four MNs (NM102, NM103, NM104, and NM105) were tested. NM 101 was also investigated by 
intratracheal instillation. The protocol of dispersion agreed on the one used within WP7. 
Dispersion protocol:  
For each MN, a solution of 2.56 mg/ml in EtOH+0.05% RSA was prepared in glass vials with a total 
volume of 22 ml and homogenized for 16 min.  
 
1.1 Intratracheal 
1.1.1    MATERIALS AND METHODS  
1.1.1.1 Preparation of exposure suspensions  
TiO2 samples were prepared according to the dispersion protocol established by WP4. In short, a 
2.56 mg/ml stock suspension was prepared by prewetting the TiO2 powder in 0.5 vol % ethanol 
followed by dispersion in 0.05 wt% Rat Serum Albumin (RSA) in ultrapure water. The sonication of 
the suspensions was performed on ice (Branson Sonifier S-450D, Branson Ultrasonics Corp., Danbury, 
CT, USA, equipped with a disruptor horn Model number: 101-147-037) for 16 minutes on ice/water. 
The stock suspensions were diluted (9:1 vol/vol) with 10x concentrated phosphate buffer pH 7.4 (702 
mg NaH2PO4 x2H2O, 4155 mg Na2HPO4  x7H2O, dissolved in 1L) and used immediately. 
1.1.1.2 Dynamic Laser Scattering (DLS) of TiO2 suspensions  
The hydrodynamic particle number/size distribution of the particles in the exposure liquids were 
analysed by photon correlation spectroscopy using a Dynamic laser scattering DLS Zetasizer nano ZS 
(Malvern Inc., UK.). The number distributions were calculated by the DTS software using the viscosity 
for H2O (0.6864), temperature of 25 ºC and material refractive (Ri) and absorption indices (Rs) for 
TiO2 (Anatase: Ri 2.49; Rs 0.10 and rutile: Ri 2.90; Rs 0.10). NM-105 contains 85% anatase and was 
analysed as anatase. Vehicle controls were analysed using both settings. Scans were performed on all 
samples to determine optimal measure parameters. A laser attenuation factor of 2 and 
measurement position of 0.45 mm was optimal for all TiO2 containing samples. It was not possible to 
find optimal parameters for samples without TiO2 particles (Vehicle control). These were analysed 
using a laser attenuation factor of 7 and a measurement position of 4.65 mm. All samples were 
analysed within 30 min after sonication, i.e. within the same time frame as the oral exposures 
occurred. Data quality was analysed by evaluating the intensity correllelogram, cumulants fit and the 
distribution fit of the laser scattering intensity data.  
 
 
 
   
Grant Agreement n° 2009 21 01 
 
 
The NANOGENOTOX Joint Action is co-funded by the Executive Agency 
 for Health and Consumers (Grant Agreement n°2009 21 01) under 
the European Union 2nd Health Programme. 
 
www.nanogenotox.eu 
12 
1.1.1.3 Animals and caging conditions 
Male Sprague Dawley rats, 4-5 weeks old were obtained from Taconic (Ry, Denmark). The rats were 
randomly divided into groups of 2-3 housed in polypropylene cages with pinewood sawdust bedding 
and aspen wood enrichment (Brogaarden, Denmark). The cages were stored in rooms with a 12 h 
light period from 6 a.m. to 6 p.m., and the temperature and relative humidity in the animal room 
were 21 ± 2°C and 50 ± 5%, respectively. The cages were sanitized twice weekly. All rats were given 
free access to tap water and standard mouse chow diet (Altromin no. 1324, Christian Petersen, 
Denmark). The rats were kept under pathogen-limited conditions and were allowed to acclimatize for 
2-3 weeks before they entered the experimental protocol. All rats were 6-7 weeks old at exposure 
start. All animal procedures followed the guidelines for the care and handling of laboratory animals 
established by the Danish government, and the Animal Experiment Inspectorate under the Ministry 
of Justice, approved the study (#2010/561-1779).   
1.1.1.4 Experimental protocol (materials and doses) 
The rats were exposed to 3 intratracheal instillations on each of 3 consecutive days. They were 
sedated by 4% isoflurane inhalation before (not during) the instillation procedure. A BD autoguard 
16GA (1.7x45 mm, ref: 381857) and a 1 ml syringe was used for the instillation. It was filled with 400 
µl of air followed by 200 µl suspension/100g body weight. Animals were dosed with a high (4.6 
mg/kg), middle (2.3 mg/kg) or low dose (1.15 mg/kg) of 5 TiO2s (NM-101, -102, -103, -104 and -105). 
Additionally, vehicles (Nanogenotox protocol or MilliQ) and MMS (25 mg/kg oral) were tested. The 
experiment was terminated 3h after last instillation, where the rats were sedated by a minimum of 
60 mg/kg of Pentobarbital with lidokain. 
1-5  Vehicle  (Nanogenotox Protocol)   x3 days 
6-10  Vehicle  (MilliQ)   x3 days 
11-15  NM-101  (Nanogenotox protocol)  4.6mg/kg  x3 days 
16-20  NM-101  (Nanogenotox protocol)  2.3mg/kg  x3 days 
21-25 NM-101  (Nanogenotox protocol)  1.15mg/kg  x3 days 
26-30  NM-102  (Nanogenotox protocol)  4.6mg/kg  x3 days 
31-35  NM-102  (Nanogenotox protocol)  2.3mg/kg  x3 days 
36-40  NM-102  (Nanogenotox protocol)  1.15mg/kg  x3 days 
41-45  NM-103  (Nanogenotox protocol)  4.6mg/kg  x3 days 
46-50  NM-103  (Nanogenotox protocol)  2.3mg/kg  x3 days 
51-55  NM-103  (Nanogenotox protocol)  1.15mg/kg  x3 days 
56-60  NM-104  (Nanogenotox protocol)  4.6mg/kg  x3 days 
61-65  NM-104  (Nanogenotox protocol)  2.3mg/kg  x3 days 
66-70  NM-104  (Nanogenotox protocol)  1.15mg/kg  x3 days71-75  NM-105 
 (Nanogenotox protocol)  4.6mg/kg  x3 days 
76-80  NM-105  (Nanogenotox protocol)  2.3mg/kg  x3 days 
81-86  NM-105  (Nanogenotox protocol)  1.15mg/kg  x3 days 
106- 110  MMS Positive Control (Saline)  oral 25mg/kg  x3days 
111-115  Unexposed Controls 
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1.1.1.5 Broncho Alveolar Lavage (BAL) and isolation of organs  
BAL was withdrawn by flushing the lungs five times with 5 ml 0.9% sterile saline through the trachea. 
The BAL fluid was briefly centrifuged (400g, 10 min, 4°C) and the total number of live/dead cells was 
determined by NucleoCounter (ChemoCounter, Denmark). The remaining cells were used for a 
cytospin slide and comet preparations (with 10% DMSO, stored at -80°C). The collected organs were 
lung, liver, kidney, and spleen. Small tissue sections of 20-40mg of each organ were snap frozen in 
liquid N2 and then transferred to -80 °C.  
1.1.1.6 Comet and micronucleus assay 
For the comet analysis, the tissue sections were in frozen state placed in a metal stapler (diameter 
0.5 cm, mesh size 0.4 mm) and quickly homogenised into ice cold Merchant’s media for a single cell 
preparation and protection. BAL or tissue cells were mixed with low melting point agarose (10 µl:90 
µl) and 30 ul gels were cast on Trevigen 20 well slides. Final agarose concentration was 0.7%. After 
overnight lysis the slides were subjected to electrophoresis (38V (1.15V/cm), 292-300 mA; 40 min for 
BAL cells and 30 min for tissues). The slides were dried and stained (SYBR Green) before being 
imaged on a fluorescence microscope (Olympus BX41; 100x magnification) equipped with an Allied 
Dolphin F-145B camera (Vision Technologies) and the automated Imstar Pathfinder scoring system 
(Imstar, France). Both femurs were collected for micronucleus scoring. Slides were prepared, dried 
and shipped to the scoring laboratory.  
The FpG-Comet assay has not been performed. Several tests were unsuccessful, and FpG results will 
therefore not be included in this report for intracheal instillation of TiO2.   
The bone marrow from both femurs (separate) was flushed out using 5 ml impuls cytofotometer 
solution (tri-sodiumcitrate-dihydrate 3.22 g, sodium dihydrogen phosphate dihydrate 3.40 g, 
disodium hydrogenphosphate dehydrate 3.87 g, citricacid monohydrate 1.17 g, glucose 3.65 g,  
sodiumchloride 4.96 g, dest.H2O ad 1000 ml). Fifty µl of the well mixed cell suspension was used for 
a cytospin slide. All slides were May-Grünwald – Giemsa stained before being sent to the scoring 
laboratory for analysis.  
1.1.1.7 Statistical analysis 
All comet assay results are shown as mean of five medians ± SD. Statistics was performed by non-
parametric Kruskal-Wallis one-way test. Identical analyses were also performed with non-parametric 
Mann-Whitney U-test yielding very similar results. Statistical analysis was performed using Minitab 
15 (Minitab Ltd. UK). The statistical significance was set at p < 0.05.  
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1.1.2 RESULTS 
1.1.2.1 Broncho alveolar fluid cytology 
 
Viability of the BAL cells was between -9% and +11% (NM-101 and NM-105 High Dose, respectively) 
compared to unexposed rats. Nanogenotox vehicle exposed rats had a 3% reduced viability 
compared to unexposed rats. Figure 3 illustrates the particle induced changes in total cell number as 
well as in composition of cells in the BAL fluid. 
 
 
 
1.1.2.2 Comet assay 
 
 
 
Figure 1.1.1. Particle induced changes in the numbers and composition of BAL cells. Visual 
identification of neutrophils, macrophages, eosinophils, epithelial cells and lymphocytes from control 
and exposed rats. Results represent mean ± SD. 
 
1.1.2.2 Comet assay 
 
The comet assay imaging/scoring was performed on BAL cells, lung, liver, spleen and kidney tissue.  
In BAL, lung and kidney, the level of genotoxicity was not increased for any of the TiO2 exposed 
groups (Figure 1.1.2). 
 
 
 
 
 
Figure 3. Particle induced changes in the numbers and composition of BAL cells. Visual identification 
of neutrophils, macrophages, eosinophils, epithelial cells and lymphocytes from control and exposed 
rats. Results represent mean ± SD. 
 
   
Grant Agreement n° 2009 21 01 
 
 
The NANOGENOTOX Joint Action is co-funded by the Executive Agency 
 for Health and Consumers (Grant Agreement n°2009 21 01) under 
the European Union 2nd Health Programme. 
 
www.nanogenotox.eu 
15 
 
All materials showed a dose dependent increase in neutrophils. However, the influx of neutrophils 
was much greater with materials NM-103, NM-104 and NM-105 (hydrophobic rutile, hydrophilic 
rutile and 15% rutile) compared to NM-101 and NM-102 (anatase).  
1.1.2.2 Comet assay 
 
Imaging/scoring of the comet assay was performed on BAL cells, lung, liver, spleen and kidney tissue.  
 
In BAL and lung, the level of genotoxicity was not increased for any of the TiO2 exposed groups 
(Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Genotoxicity measured as median %DNA in the tail. The mean of five medians ± SD are 
shown for BAL cells (A) and lung (B) after TiO2 intratracheal instillation to rats. MMS was used as a 
chemical positive control. MQ= in MilliQ water.  
A 
B 
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In liver, spleen and kidney, the level of genotoxicity was not increased for any of the TiO2 exposed 
groups (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
B 
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Figure 5. Genotoxicity measured as median %DNA in the tail. The mean of five medians ± SD are 
shown for Liver (A), spleen (B) and kidney (C) after TiO2 intratracheal instillation to rats. MMS was 
used as a chemical positive control. MQ= in MilliQ water.  
 
 
All TiO2 materials caused pulmonary inflammation determined as influx of neutrophils. Largest 
inflammation was caused by the rutile containing NM-103, NM-104 and NM-105. However, no 
statistical effect was noted on the genotoxicity in any of the tested organs. These results are in line 
with one of our previous studies were instillation of TiO2 caused pulmonary inflammation but no 
genotoxicity (Saber et al., 2012). 
 
Very low median values were observed for some organs (BAL cells, spleen and partly liver). All of 
these results show much higher values when viewed as tail-length and mean % DNA in tail. It 
therefore appears that for some organs a majority of cells are less damaged than a minority. 
However, for all mentioned measures the conclusion would be the same; no statistically significant 
genotoxicity observed.  
 
Our median values may also be slightly lower than others due to the corrections made by the Imstar 
Pathfinder system. This system corrects for the halo of DNA diffused in all directions. This amount of 
DNA is subtracted from the tail.   
 
 
 
 
 
 
C 
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1.1.2.3 Micronucleus assay 
 
A total of 230 slides were received in duplicate Bone marrow slides of 40 animals out of 115 could 
not be read due to the abundance of cells in the slide preparation. Both slides from the right and the 
left femurs were scored. 
No increase in micronucleus frequency was induced in all the TiO2 exposed groups (Table 4). 
 
Table 4: Genotoxicity (frequency of micronucleated Immature Erythrocytes) and toxicity (PCE/NCE 
ratio) induced in bone marrow by TiO2 following intratracheal instillation. Positive control MMS was 
administered by gavage as described in the Material & Methods. PCE = polychromatic erythrocytes; 
NCE = normochromatic erythrocytes 
Micronucleated
Cells
 Mean
0 0,323 0,150 10 0,047 1,203 0,228 10 0,072
4,6 0,350 0,235 6 0,096 1,662 0,313 6 0,128
2,3 0,386 0,090 7 0,034 1,675 0,443 7 0,167
1,15 0,313 0,164 8 0,058 2,044 0,647 8 0,229
MMS 25 1,320 0,239 5 0,107 1,334 0,107 5 0,048
0 0,323 0,150 10 0,047 1,203 0,228 10 0,072
4,6 0,430 0,116 10 0,037 1,180 0,210 10 0,066
2,3 0,525 0,249 8 0,088 1,593 0,391 8 0,138
1,15 0,388 0,136 8 0,048 1,485 0,447 8 0,158
MMS 25 1,320 0,239 5 0,107 1,334 0,107 5 0,048
0 0,323 0,150 10 0,047 1,203 0,228 10 0,072
4,6 0,343 0,190 7 0,072 1,307 0,431 7 0,163
2,3 0,214 0,135 7 0,051 1,840 0,521 7 0,197
1,15 0,250 0,122 6 0,050 1,893 0,404 6 0,165
MMS 25 1,320 0,239 5 0,107 1,334 0,107 5 0,048
0 0,323 0,150 10 0,047 1,203 0,228 10 0,072
4,6 0,125 0,126 4 0,063 1,744 0,266 4 0,133
2,3 0,217 0,117 6 0,048 1,890 0,471 6 0,192
1,15 0,150 0,100 4 0,050 1,732 0,198 4 0,099
MMS 25 1,320 0,239 5 0,107 1,334 0,107 5 0,048
0 0,323 0,150 10 0,047 1,203 0,228 10 0,072
4,6 0,200 0,089 6 0,037 2,059 0,709 6 0,290
2,3 0,433 0,266 6 0,109 1,631 0,389 6 0,159
1,15 0,371 0,125 7 0,047 2,427 0,725 7 0,274
MMS 25 1,320 0,239 5 0,107 1,334 0,107 5 0,048
Genotoxicity Toxicity
[mg/kg]
SD n SE
PCE/NCE 
ratio 
Mean
SD n SE
NM 101
NM 102
NM 103
NM 104
NM 105
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1.1.2.4 DLS of TiO2 suspensions  
The number/size distribution of the suspended TiO2 particle preparations used for oral gavage was 
characterised by dynamic light scattering (DLS). Analysis of the vehicle solution was challenging, and 
the DTS software could not establish optimal measuring parameters. The count rate and the results 
(Ζ-average, intensity) varied highly between each of the 12 analysis, leading to a high Polydisperty 
Index and unreliable DLS data. Analysing the vehicle for rutile or anatase TiO2 did not influence the 
results. 
All TiO2 containing suspensions yielded reliable results according to the DTS software (Table 5). The 
majority of particles occurred as agglomerates between 80–150 nm (peak number distributions, 
Figure 6). Suspensions of NM-103, NM-104 and NM-105 contained the smallest agglomerates (80-90 
nm) whereas the largest agglomerates were observed with NM-101 and NM-102 (140-150 nm). NM-
101 and NM-102 additionally showed a bi-modal size-distribution with another much less frequent 
mode of ~1 µm. No agglomerates were observed between 3 µm and 10 µm (the upper limit of the 
Zetasizer nano ZS) for any of the materials.   
Table 5. Z-average (intensity distribution peak) and Polydispersity Index (PdI) of the TiO2 suspensions 
used for oral gavage. Results are the mean of 12 analyses conducted on two separate days. *A high 
Polydispersity Index means unreliable data. 
 
 
 
 
 
 
 
 
Material Conc. Vehicle Z-Average (int) PdI 
     
NM-101 2.56 EtOH/RSA/PBS 278 nm 0.323 
NM-102 2.56 EtOH/RSA/PBS 367 nm 0.290 
NM-103 2.56 EtOH/RSA/PBS 127 nm 0.384 
NM-104 2.56 EtOH/RSA/PBS 108 nm 0.274 
NM-105 2.56 EtOH/RSA/PBS 93 nm 0.151 
Control 0.00 EtOH/RSA/PBS 477 nm 0.817* 
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Figure 6. Hydrodynamic number/size distribution of NM-101, -102, -103, -104 and -105 (left and 
right). The majority of particles were observed as agglomerates between 50-200 nm. Suspensions of 
NM-101 and NM-102 contained an additional mode between 250 and 2500 nm. No agglomerates 
were observed above 3 µm. Results are the mean of 12 analyses conducted on two separate days. 
 
 
1.2 Gavage 
 
1.2.1 MATERIALS AND METHODS 
1.2.1.1 Animals 
Male, 8- 10 weeks old Wistar rats were obtained from the animal facility of the Bulgarian Academy of 
Sciences (EBBA-BAS, Slivnitsa, Bulgaria). They were randomly assigned to 4 experimental groups, with 
two controls (placebo and positive (MMS) control) with five animals per group. Following 5-10 days 
of adaptation, one millilitre of TiO2 (NM102, -103,-104, and -105) dispersion, vehicle and MMS were 
given by gavage once daily for 3 consecutive days. Three hours following the last gavage, the animals 
in different groups were anaesthetised with ketamine (100 mg/kg b.w) and sacrificed. Tissue and 
blood collections are described below. During all housing period the animals were kept in Tecniplast 
cages at a room temperature of 21 ± 2°C, a relative humidity of 50 ± 5% and a 12-h light/dark cycle. 
The drinking water and conventional feed (Complete lab chow, Topmix Ltd, Kaloyanovo, Bulgaria) 
were provided ad libitum. These experiments were approved by the Animal Research Committee of 
the Institute of Neuroscience – BAS (Protocol N 27/02.06.2011) prior to the study. 
 
1.2.1.2 MN Sample preparation 
MNs samples were prepared according to the dispersion protocol developed within WP4. In short, a 
2.56 mg/ml stock suspension was prepared by pre-wetting the TiO2 powder in 0.5 vol % ethanol 
followed by dispersion in 0.05 wt% Rat Serum Albumin (RSA) in ultrapure water. The sonication of 
the suspensions was performed on ice (Cell Disruptor Sonicator W-375 (Ultrasonic Inc.)) for 16 
minutes at 40% power output.  The stock suspensions were used for the gavage within 30 min. 
 
   
Grant Agreement n° 2009 21 01 
 
 
The NANOGENOTOX Joint Action is co-funded by the Executive Agency 
 for Health and Consumers (Grant Agreement n°2009 21 01) under 
the European Union 2nd Health Programme. 
 
www.nanogenotox.eu 
21 
Methyl methanesulfonate (MMS) was purchased from Sigma Aldrich (ref# 129925), diluted in 0.9% 
NaCl and administered by gavage. 
 
1.2.1.3 Tissue collection and cells’ isolations 
Blood samples from treated animals were collected together with liver, spleen, kidney, jejunum, 
colon, tibia and feces. Immediately after collection, the bone marrow cells and epithelial cell from 
the colon and jejunum were isolated in Epithelium growth media (EBM) or Bone marrow one, and 
were frozen at -80 °C (in cell protected media) until further analysis.   
 
 Bone marrow isolation   
Following the dissection and cleaning of tibia, both ends of the bone were opened and flushed with 6 
ml serum into a 50 ml tube. The suspensions were mixed well with a sterile pipette and load on cell 
strainers (70 and 50 µm mesh), centrifuged at 170 g for 10 min at 23 °C (Eppendorff 5430R) and wash 
two times with EBM media. The supernatant was removed and the remaining cell pellet was 
suspended in 2 ml EBM. The cells for comet assay were frozen in EBM media containing 20%FBS and 
10% DMSO until further analysis.  
 
 Lymphocytes isolation 
Blood sample (+anticoagulant): 1 ml PBS (or 1ml RPMI medium (w/o PhenolRed)+10% FCS) was 
added to the 30 µl blood in a 1.5 ml Eppendorf tube. Mixed and kept on ice for 30 min. Then 
underlay with 100 µl Histopaque 1077 (Sigma), using a pipette. Span at 200 x g, 3 min, 4°C. 
Lymphocytes were retrieved in 100µl in the layer just above the boundary between PBS (RPMI) and 
Histopaque. They were washed with 1 ml PBS and centrifuged again. The supernatant was removed 
as much as possible and kept for comet analysis. 
 
 Liver, kidney and spleen cells isolation   
Cells from liver, kidney and spleen were obtained by enzymatic tissue dissociation using a mixture of 
Collagenase type IA and papain (Sigma Aldrich) at 37 °C for 1h. In case of incomplete dissociation the 
samples were further destructed by pipetting or with Xenox motorized hand tool. The cell 
suspensions were filtered through cell strainers (70 and 50 µm, Fisherbrand)) and frozen at -80 °C in 
cell protected media until further analysis. 
 
 Colon and Jejunum  
Following the washing of the colon and the intestine with PBS they were open and the internal side 
was scratched with a scrapper and mixed with EBM media. The mixtures were pippeted up-down 
several times and were filtered through cell strainer (50 µm, Fisherbrand). The cell suspension was 
centrifuged at 800 x g for 5 min and the resulting pellet was washed twice with PBS. Finally the cells 
were used immediately for comet assay or stored at -80 °C in cell protected media until further 
analysis. 
 
The counting of the cells was performed using an automated cell counter Countess (Invitrogen) 
following staining with Trypan blue.  
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1.2.1.4 Comet assay  
The alkaline version of the comet assay was performed following the recommendations of Tice et al. 
(Tice et al. 2000), Burlinson (Burlinson et al. 2007), and Guidance on a Strategy for Testing of 
Chemicals for Mutagenicity (2000). The formamidopyrimidine DNA glycosylase (FpG) was used to 
detect oxidative DNA damage according to Collins et al (Collins et al. 2008).  
Briefly, cells were embedded in 0.8 % of low melting agarose (Invitrogen) and spread on microscope 
slides pre-coated with 1 % agarose or GelBond films (Lonza). After lysis for 1h at 4°C (buffer: 2.5 M 
NaCl, 100 mM Na2-EDTA, 10 mM Tris-HCl, pH10, 10 % DMSO and 1 % Triton X100) and equilibration, 
the electrophoresis was performed in buffer containing 0.3 M NaOH and 1 mM EDTA (25V, ~300 mA, 
30 min at 4°C). Following electrophoresis the slides or films were neutralized by 3 x 5 min washes 
with neutralizing buffer (0.4 M Tris, pH 7.5) in horizontal staining jars at 4°C and the excess of the 
neutralizing buffer was carefully blotted with filter paper. The slides were washed twice with 
ultrapure water for 5 min and dehydrated for 10 min into 96% ethanol before being dried at 45°C 
and stored in the dark at room temperature. 
For FpG comet assay, the films were supported by slides, washed three times in enzyme buffer (50 
mM Na3PO4, 10 mM EDTA, 100 mM NaCl, pH 7.5), drained and incubated with 50 μl of either buffer 
or FpG (Sigma Aldrich, USA) (1 μg/ml in enzyme buffer) placed onto gel and cover with cover slip, and 
then transferred into moist box (prevents desiccation), and incubate at 37ºC for 30 min. The slides 
were then placed in a horizontal gel electrophoresis tank filled with fresh alkaline buffer (1 mM 
Na2EDTA and 300 mM NaOH, pH 13) for 40 min at 4°C to allow denaturing and unwinding of the DNA 
and the expression of alkaline-labile sites. The running conditions were the same as above. 
For scoring, the slides were stained with 4’6-diamidine-2-phenylindol dihydrochloride (DAPI, 1µg/ml). 
Pictures were taken with a fluorescence microscope (Axiovert 200M, Zeiss) and the analyses were 
performed with TriTek CometScore™ software (TriTek Corporation). A minimum of 100 nucleoids per 
slide were scored and the percentage of DNA in the tail was recorded.  
 
1.2.1.5 Titanium content analysis 
Atomic emission spectrometer with inductively coupled plasma (ICP-OES, ULTIMA 2, HORIBA Jobin 
Yvon) was used for the determination of titanium concentration in samples solutions (optimal 
instrumental parameters are presented in details in Deliverable #7 for NM-105). Results obtained are 
calculated and expressed as micrograms Ti or TiO2 per gram fresh tissue or faeces. 
 
 Tissue analysis 
Titanium content analysis in the tissue samples were performed according to the protocols 
developed in WP7 for NM-105.  
 
 Feces analysis 
The collection of feces began following the first gavage and ended at the time of euthanizing. All 
collected feces were kept frozen until the analysis. Frozen feces were homogenized and two parallel 
samples were digested according to the procedure: About 1 g sample was weighed in a high pressure 
Teflon vessels for microwave digestion, 5 ml c.HNO3 (ultrapure grade, Merck) were added and 
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samples left to stay overnight (8 hours). Than 0.5 ml HF (ultrapure grade, Merck) were additionally 
added and samples were digested in a microwave assisted digestion system (CEM MARS, USA) 
according to the program: step 1: 5 min at 300W; step 2: 5 min at 600W. After cooling the solutions 
were quantitatively transferred to plastic tubes and diluted to 12 ml with Milli Q water.  
 
 Food analysis 
Procedure for food analysis: About 0.5 g complete lab chow (Topmix Ltd, Kaloyanovo, Bulgaria) was 
weighed in a high pressure Teflon vessels for microwave digestion, 5 ml c. HNO3 (ultrapure grade, 
Merck) were added and samples left to stay overnight (8 hours). Than 0.3 ml HF (ultrapure grade, 
Merck) were additionally added and samples were digested in a microwave assisted digestion system 
(CEM MARS, USA) according to the program: step 1: 5 min at 300W; step 2: 5 min at 600W. After 
cooling the solutions were quantitatively transferred to plastic tubes and diluted to 10 ml with Milli Q 
water.  
 
 
1.2.1.6 Statistical analysis 
Results were expressed as mean ± standard deviation. For Ti concentrations multigroup comparisons 
of the means were carried out by one-way analysis of variance (ANOVA) followed by Bonferroni’s 
test to compare the differences between the groups.  
The results from comet assay were analysed by multi-group comparisons of the means were carried 
out by Mann–Whitney U test followed by Jonckheere-Terpstra trend test (PASW Statistics 18.0, IBM, 
USA). The statistical significance for all tests was set at p < 0.05. 
 
1.2.2 RESULTS 
 
1.2.2.1 Toxicity 
 
The gavage performed with NM 102, 103, and 104 was well tolerated in all animals studied, with 
exception of NM 105 (26 mg/kg b.w) where diarrhea was registered in 3 animals on day 3. In all other 
animals no adverse effects were observed during the experiment. 
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1.2.2.2 Comet assay 
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Figure 7. DNA fragmentation assessed by the comet assay without FpG in the organs and tissues 
from the rats treated by gavage with TiO2 nanomaterials for 3 consecutive days.  All data are 
presented as mean of the median of the present DNA in the tail (Mann-Whitney test, * p<0.05). 
 
 
The data following assessment of oxidative DNA fragmentation in the colon detected by comet assay 
using FpG are shown in Figure 8. 
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Figure 8.  Oxidative DNA damage in the colon of rats exposed to TiO2 at the indicated doses using a 
comet assay without formamidopyrimidine DNA glycosylase (FpG-) and with FpG+. 0: controls animals; 
MMS: Methylmethanesulfonate (positive control). Results are expressed as % DNA in Tail. Mean ± SD 
are shown, from five different animals with duplicate cell samples. (Mann-Whitney test, * p<0.05) 
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The data following assessment of oxidative DNA fragmentation in the jejunum detected by comet assay 
using FpG are shown in Figure 9. 
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Figure 9.  Oxidative DNA damage in the jejunum of rats exposed to TiO2 at the indicated doses using a 
comet assay without formamidopyrimidine DNA glycosylase (FpG-) and with FpG+. 0: controls animals; 
MMS: Methylmethanesulfonate (positive control). Results are expressed as % DNA in Tail. Mean ± SD 
are shown, from five different animals with duplicate cell samples. (Mann-Whitney test, * p<0.05) 
 
 
1.2.2.3 Micronucleus assay 
 
 Bone marrow 
 
Table 6. Percentage of polychromatic erythrocytes (PCE) micronucleous (PCEMN) in the micronucleus 
test in vivo following gavage with TiO2 nanomaterials for 3 consecutive days 
 
 Colon 
The slides from the colon micronucleus assays are still under scoring and the results cannot be 
presented in this deliverable. 
 
1st lab 
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1.2.2.4 Tissue distribution 
All six organs investigated (liver, kidney, spleen, stomach, jejunum, and colon) following gavage 
administration of MNs for 3 consecutive days, showed a small detectable Ti content only for the 
highest dose used (24-31 mg/kg b. w). The highest Ti concentrations detected in the liver and spleen 
were for NM-105 – 270±0.06 ng/g tissue and 243±140 ng/g tissue respectively (Figure 10). For all 
other MNs tested Ti concentration in the spleen was about 170±50 ng/ g tissue. The presence of Ti in 
the GI tract was also detected and the results are shown in (Figure 11).  
 
The Ti concentration within the organs of Wistar rats treated with NM-105 were measured by ICP-
OES following the methods developed in WP7. 
 
Figure 10. Distribution of Ti in the organs of rats treated by gavage with 2.56 mg/ml NM105. Each bar 
repre  sents the mean of 5 test animals (mean ± SD). DL: below the detection limit.  
 
 
Figure 11. Distribution of Ti in the organs of rats treated by gavage with 2.56 mg/ml TiO2 for 3 
consecutive days. Each bar represents the mean of 5 test animals (mean ± SD). 
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After the repeated TiO2 nanomaterial administration very high Ti levels were detected in the faeces 
(Table 7), as an indication of MNs extraction vie GI tract.  
 
Table 7 Presence of Ti (μg) in faeces of TiO2 treated animals 
 
 
1.3 Intravenous administration in rats 
 
1.3.1 MATERIALS AND METHODS 
 
During an experiment performed in the toxicokinetics workpackage for the tissue distribution of NM-
103 and NM-104, extra bone marrow samples were obtained for evaluation of the presence of 
micronuclei. In this experiment animals received a single (day 1) or repeated (five times on five 
consecutive days, day 1 to day 5) intravenous administration of TiO2 NM-103 and NM-104. 
 
1.3.1.1 Animals 
Animals were bred under specific pathogen-free (SPF) conditions and barrier maintained during the 
entire experiment in Macrolon cages at a room temperature of 23 ± 1°C, a relative humidity of 50 ± 
5% and a 12-h light/dark cycle. Standard feeding chow diet and water were provided ad libitum. Rats 
were randomly divided into groups of 1-3/cage. The rats were kept under pathogen-limited 
conditions and were allowed to acclimatize for 1-2 weeks before they entered the experimental 
protocol. All rats were 9-10 weeks at exposure start. 
 
1.3.1.2 MN Sample preparation 
TiO2 samples were prepared according to the dispersion protocol by WP4. In short, a 2.56 mg/ml 
stock suspension was prepared by pre-wetting the TiO2 powder in 0.5 vol % ethanol followed by 
dispersion in 0.05 wt% Rat Serum Albumin (RSA) in ultrapure water. The sonication of the 
suspensions was performed on ice (Branson Sonifier S-450D, Branson Ultrasonics Corp., Danbury, CT, 
USA, equipped with a disruptor horn Model number: 101-147-037) for 16 minutes at 10% power.  
The stock suspensions were diluted (9:1 v/v) with 10x concentrated phosphate buffer (2mM) pH 7.4 
(702 mg NaH2PO4 x2H2O, 4155 mg Na2HPO4  x7H2O, dissolved in 1L) and used immediately. 
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1.3.1.3 IV administration of NM-103, and NM-104 
The TiO2 doses for the IV route were administered using a TiO2 dispersion containing 2.30 mg TiO2  
per ml.  The single dose groups received a dose per animal of 2.3 mg per animal resulting in a dose 
between 8.7 – 9.7 mg/kg body weight (b.w.) for male animals, and 12.4 – 13.7 mg/kg b.w. for female 
animals depending on the actual weight of the animal (weight range males 238 g – 265 g, females 
168 g – 186 g at the start of the experiment).  
The repeated dose groups received total cumulative dose per rat between 43.5 – 48.5 mg/kg b.w. for 
male rats, and 62 – 68.5 mg/kg b.w. for female rats depending on the actual weight of the animal. All 
experiments were approved by an independent Ethical Committee on Animal Experimentation and 
conducted in compliance with all applicable provisions of the national laws of the Netherlands i.e., 
the Experiments on Animal Decree and the Experiments on Animal Act. Study numbers were: DPA 
registration 201000255, 201000287, and 201100309. 
As positive control for the induction of micronuclei in the bone marrow, methyl methanesulfonate 
(MMS) was used. Animals received either a single an IV administration of 30 µg/kg, or a repeated IV 
administration for 5 days (days 1 to 5) of 30 mg/kg resulting in a cumulative dose of 150 mg/kg. 
 
1.3.1.4 Bone marrow isolation, staining and scoring 
After IV administration of NM-103, NM-104, and MMS the rats were anaesthetized by inhalation of 
isoflurane (Isoflu®, AST Pharma, Oudewater, The Netherlands) in oxygen and subsequently 
euthanized by drawing blood from the abdominal aorta. For evaluation of micronuclei in the bone 
marrow, bone marrow cells were isolated by flushing the right femur with  4 ml of ICD ( Impuls 
Cytophotometer) solution consisting of  tri-sodiumcitrate-dihydrate (3.22 g), sodium dihydrogen 
phosphate-dihydrate (3.40 g), disodium hydrogenphosphate- dehydrate (3.87 g),  citric acid-
monohydrate (1.17 g),  glucose (3.65 g),  sodium chloride (4.96 g), and aqua destillata ad 1000 ml.  
The solution has a pH 7.4 at 20 °C, and was stored for maximally one month at 4 °C. 
Bone marrow cells were isolated at 24 h after a single IV administration, and at 24 h after the last of 
five repeated IV administrations on day 1 to 5. A cytospin preparation was prepared in a cytospin 
centrifuge (Shandon Cytospin 2, Shandon, Thermo Shandon, Pittsburg, USA), and cells were fixed 
with methanol abs. and stained by May-Grünwald–Giemsa stain [May-Grünwald solution: 50% 
May-Grünwalds eosine-methyleneblue solution (Merck KGaA, Darmstadt, Germany) and 50% water. 
Giemsa solution: Giemsa stain (Fluka, Sigma-Aldrich, St Louis, USA), 8% v/v solution in water]. 
 
Evaluation  
Using light microscopy approximately 500 cells were evaluated for determining the frequency of 
immature erythrocytes. The number of immature erythrocytes was between 50% and 65% of the 
number of erythrocytes present in the bone marrow. At least 1000 immature erythrocytes were 
scored for the presence of a micronucleus. 
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1.3.2 RESULTS 
 
No increase in the micronucleus frequency was induced in all the TiO2 exposed animals, irrespective 
of the gender (Table 8). 
 
Table 8: Genotoxicity (frequency of micronucleated Immature Erythrocytes) and toxicity (PCE/NCE 
ratio) induced in bone marrow by TiO2 following intravenous administration. Positive control MMS 
was administered by gavage as described in the Material & Methods. PCE = polychromatic 
erythrocytes; NCE = normochromatic erythrocytes 
 
Micronucleated
Cells
 Mean
0 0,050 0,058 4 0,029 1,347 0,155 4 0,077
M 0,050 0,071 2 0,050 1,320 0,023 2 0,016
F 0,050 0,071 2 0,050 0,950 0,038 2 0,027
MMS 25 2,150 0,423 6 0,173 1,512 0,199 6 0,081
0 0,050 0,058 4 0,029 1,347 0,155 4 0,077
M 0,050 0,058 4 0,029 1,216 0,107 4 0,053
F 0,125 0,096 4 0,048 1,460 0,176 4 0,088
MMS 25 2,150 0,423 6 0,173 1,512 0,199 6 0,081
0 0,125 0,096 4 0,048 1,594 0,421 4 0,210
M 0,183 0,098 6 0,040 1,664 0,209 6 0,085
F 0,217 0,117 6 0,048 1,123 0,313 6 0,128
MMS 25 3,400 0,716 6 0,292 0,672 0,155 6 0,063
0 0,125 0,096 4 0,048 1,594 0,421 4 0,210
M 0,217 0,172 6 0,070 1,211 0,183 6 0,075
F 0,050 0,084 6 0,034 1,257 0,135 6 0,055
MMS 25 3,400 0,716 6 0,292 0,672 0,155 6 0,063
Genotoxicity Toxicity
[mg/kg]
SD n SE
PCE/NCE 
ratio 
Mean
SD n SE
NM 103 (once a day)
NM 104 (once a day)
NM 103 (5x once a day)
NM 104 (5x once a day)
 
 
 
1.4 Intravenous administration in mice 
1.4.1 MATERIAL & METHODS 
 
The lac Z assay was performed on mice only with NM-102 which was selected according to its 
genotoxic response within the WP5 and its accumulation potency detected within the WP7. 
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1.4.1.1 Animals and treatments 
C57Bl/6 pUR288 transgenic mice  were bred, maintained, treated and sacrificed at Instituto Nacional 
de Saúde Dr. Ricardo Jorge, according to European Union directives. In these mice, the pUR288 
plasmid is inserted in head-to-tail sequences in homozygosity on both chromosomes 3 and 4 and 
contains the lacZ reporter gene. 
A dispersion of the titanium dioxide nanomaterial NM-102 was prepared according to agreed 
protocol. A solution of 2.56 mg/ml in EtOH+0.05% BSA was prepared in glass vials, homogenized by 
sonication for 16 minutes and 10x concentrated saline was added before injection in mice. Groups of 
5-6 male mice, 3 months-old, were intravenously injected twice, in consecutive days, with 0 (vehicle 
only), 10 or 15 mg/kg of body weight. The positive control, N-ethyl-N-Nitrosurea (ENU; Sigma-
Aldrich, St. Louis, MO, CAS# 759-73-9) was dissolved in dimethylsuphoxide and a dilution in saline (25 
mg/ml) was prepared for injection. One group of lacZ mice mice was intraperitoneally injected with a 
single dose of ENU, 120 mg/kg body weight. 
Mice were sacrificed 28 days later and livers and spleens were removed, flash frozen, and stored in 
liquid nitrogen until DNA extraction for lacZ mutation analysis. Part of liver and spleen were collected 
for immediate processing for the comet assay. 
 
 
1.4.1.2 Micronucleus assay 
Five microlitres of peripheral blood were obtained from a tail blood vessel 42 hr after the last 
injection. The blood was placed on acridine orange-coated slides, covered with a coverslip, and 
stored at 4ºC until analysis (Hayashi et al, 1990). For each animal, 2000 RET were blind scored under 
fluorescence microscopy. The frequency of micronucleus per 1000 RET and the percentage of RET 
were calculated for each animal and for each treatment group.  
 
1.4.1.3 Comet Assay  
The alkaline comet assay was performed in freshly-isolated liver and spleen samples that were 
placed in D-PBS with 20 mM EDTA and 10% DMSO, pH 7.0.  Tissues were minced into fine pieces, and 
5 - 10 µL of the cell suspension was embedded in low melting point agarose 1% at 38ºC.  The assay 
was performed after overnight lysis at 4ºC. DNA was then allowed to unwind for 30 min in alkaline 
electrophoresis buffer (300mM NaOH, 1mM Na2EDTA, pH>13) and electrophoresis was run for 25 
min at 0.8V/cm and 300mA, at 4ºC. Following neutralization (0.4M Tris, 4M HCl, pH 7.5), slides were 
stained with ethidium bromide (0.125 μg/μL). One hundred randomly selected nucleoids were 
analysed per mice under a fluorescence microscope (Zeiss, Axioplan 2) using the Comet Imager 
software (MetaSystems, GmbH).  
 
1.4.1.4 4. LacZ mutation assay 
Genomic DNA extraction from homogenized livers and spleen and lacZ-plasmid rescue were done 
using a previously established protocol (Louro et al, 2010). Briefly, 50 µg of genomic DNA were 
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incubated with 40 U of HindIII and with magnetic beads (Dynabeads M450 sheep antimouse IgG) 
precoated with lacZ/lacI fusion protein.The supernatant fluid was discarded and the plasmid DNA 
was eluted using isopropyl-b-D-galactopyranoside, followed by heat inactivation of HindIII at 65ºC. 
Plasmids were circularized with T4 DNA at room temperature and ethanol precipitated. The purified 
plasmid DNA was electroporated into highly competent Escherichia coli C (DlacZ and galE2) host cells. 
To determine the number of mutant colonies, the majority (99.9%) of the transformed cells were 
plated on a selective top agar plate containing the lactose analogue phenyl-b-D-galactopyranoside. 
The remainder was plated on nonselective medium containing 5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside (X-gal) to determine the total number of colonies. 
 Mutant frequency (MF) was calculated as the ratio between the number of mutant colonies and the 
total number of colonies multiplied by the dilution factor.  
 
 
1.4.2 RESULTS 
1.4.2.1 Comet assay 
 
No increase in the level of DNA damage was detected, by the alkaline comet assay, in liver and 
spleen of NM-102 exposed mice, under the tested conditions; the positive control induced a 
significant increase in the level of DNA damage in liver, even 28days after injection (Figure 12). 
 
 
Figure 12: Results from comet assay in liver and spleen 28 days after exposure of mice by i.v. to 
0, 10, or 15 mg/kg of body weight, in two consecutive days. Positive control: ethyl-nitrosourea, 
single i.p. of 120 mg/kg.  
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1.4.2.2 Micronucleus assay 
 
 
 
Figure 13: Results from micronucleus assay in blood from mice 42 h after exposure of mice by i.v. 
to 0, 10, or 15 mg/kg of body weight, in two consecutive days. Positive control: ethyl-nitrosourea, 
single i.p. of 120 mg/kg.  
 
 
1.4.2.3 LacZ mutation assay 
 
 
 
Figure 14: Results from LacZ mutation assay, 28 days after exposure of mice by i.v. to 0, 10, or 15 
mg/kg of body weight, in two consecutive days. Positive control: ethyl-nitrosourea, single i.p. of 120 
mg/kg (*significantly different from negative controls).  
 
* 
* 
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In brief for TiO2 
- Dose ranges: 
Instillation: 4.6, 2.3 and 1.15 mg/kg (x3)  
Gavage: 26, 13.5, 6.5 mg/kg (x3)  
Intravenous for NM-103 and NM-104 (WP7 experiments): 2.3 mg/animal (X5)  
Intravenous for NM-102 (LacZ): 10 and 15 mg/kg (x2) 
 
- Distribution: 
Low Ti uptake from GI was recorded  
Ti excretion detected via GI tract  
- Comet assay: 
  Most MNs induced no DNA damage irrespective of the organ  
 except after instillation NM-105 in BAL 
 and after gavage in spleen, intestine (NM-103), colon (NM-102 and -105) and bone marrow 
(NM-104) 
Genotoxic effect observed in organs depending on the route  (BAL for instillation; spleen and GI 
tract for gavage) 
- Micronucleus assays: 
 No mutagenicity in bone marrow after instillation, gavage or iv administration 
-  Lac Z (iv administration with NM102 ): 
 No genotoxicity in spleen and liver (comet) 
 No clastogenicity in blood (micronucleus)  
 No mutagenicity in liver and spleen (lac Z mutation) 
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2) SAS 
 
4 MNs (NM-200, NM-201, NM-202 and NM-203) were tested. The protocol of dispersion agreed on 
the one used within WP7. 
 
For each MN, a particle suspension solution at 6.0 mg/mL in 30 mL normal saline (NaCl 0.90% w/v) 
was sonicated 16 min with 10% amplitude in 50 mL polypropylene Falcon® tube. This protocol was 
provided by ISS scientists (Italy) who performed SAS toxicokinetics in WP7. 
 
2.1 Intratracheal instillation 
2.1.1 MATERIAL AND METHODS 
 
2.1.1.1 Animals 
Seven-week old Sprague Dawley rats were purchased from Janvier and were exposed by 
intratracheal instillation to particle suspensions or vehicle 48, 24 and 3 hours before tissue collection. 
Three concentrations were tested 12; 6 and 3 mg/kg b.w. 
 
2.1.1.2 Treatment 
For intratracheal instillation, animals were anesthetized by an intraperitoneal injection of a mixture 
of Medetomidine (Domitor, 0.25 mg/kg) and Ketamine (Clorketam 37.5 mg/kg) and 200 µL of particle 
suspensions or vehicles were then administered per 100 g of b.w using a 16 G I.V. catheter placed 
into the rat’s trachea through the mouth.  The sedative effect of medetomidine was reversed by 
subcutaneous injection of Atipamezole (Antisedan 1.25 mg/kg). 
 
2.1.1.3 Positive controls 
Methyl methanesulfonate (MMS) was purchased from Sigma Aldrich (ref# 129925), diluted in 0.9% 
NaCl and administered by gavage at a final concentration of 50 mg/kg b.w. 48 hours before tissue 
collection and then at 25 mg/kg b.w. 24 and 3 hours before tissue collection. 
N-ethyl-N-nitrosourea (ENU) was also purchased from Sigma Aldrich (ref# N3385), diluted in 0.9% 
NaCl and administered by gavage at a final concentration of 25 mg/kg b.w. 48, 24 and 3 hours before 
tissue collection. 
 
MMS was used as positive control for: 
 comet assays in BAL cells, lung, liver, spleen, bone marrow and kidney 
 micronucleus assay in bone marrow 
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ENU was used as positive control for: 
 comet assays in blood and bone marrow 
 micronucleus assay in bone marrow 
 
2.1.1.4 Tissue collection 
For tissue collection, animals were anesthetized with pentobarbital (60 mg/kg) and exsanguinated 
through the abdominal aorta. Blood was collected in K2 EDTA tubes. 
Bone marrow from the two femoral bones were collected by flushing them with a mixture of 
Sorensen buffer and Fetal Calf Serum (FCS) (1:1) using a 1 mL syringe connected to a 18G x 1 1/2’’ 
needle. Bone marrow cells were centrifuged 5 min at 400 g at 4°C. Pellets were resuspended in the 
flushing buffer and smears were made (3 for each femur). Slides were air dried, fixed with methanol 
and stored until staining.  
Remaining cells were kept on ice prior to comet assay. 
Animal chest was opened; the heart and thymus were removed. The trachea was cut as high as 
possible and the lung removed. The right primary bronchus was clipped and bronchoalveolar lavage 
was performed on the left lung using 18G canula: 4 mL of ice-cold PBS was introduced into the left 
lung and collected into a 15 mL conical tube. 4 additional lavages were performed with 4 mL of ice 
cold PBS each and were collected in second 15 mL conical tube. Both tubes were centrifuged 5 min at 
4°C at 400 x g. The supernatant from the first tube was collected for biochemical analysis using a 
Randox analyser and kept at 4°C for no more than 24 hours. The supernatant from the second tube 
was discarded and the two cell pellets were resuspended in 1 mL of ice cold PBS for cell count, 
cytospin preparation and comet assay. 
 
Cell counts were performed using a Cellometer (Nexcelom) and after Acridine Orange/Propidium 
Iodide cell staining. Differential cell counts were performed on cytospin preparation stained with 
May Grunwald Giemsa technique, 500 cells/animal were then analyzed. 
 
The left lung was kept in ice cold PBS before enzymatic tissue dissociation using Collagenase type IA 
(Sigma Aldrich ref# C9891) and Miltenyi Biotec Gentle Max dissociator. 
 
The right caudal lung lobe was fixed with 10% neutral buffered formalin (Sigma Aldrich) and paraffin 
block was made. 
 
Cells from liver, kidney were obtained by enzymatic tissue dissociation using Collagenase type IA 
(Sigma Aldrich ref# C9891) and Miltenyi Biotec Gentle Max dissociator. Cells from spleen were 
obtained by mechanical dissociation using the Miltenyi Biotec Gentle Max dissociator. 
 
One of the kidneys and pieces of liver and spleen were fixed with 10% neutral buffered formalin 
(Sigma Aldrich) and paraffin blocks were made. 
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2.1.1.5 Comet assay 
Cells were mixed with 1% low-gelling agarose (Sigma Aldrich ref# A9414) and poured onto 
microscope glass slides pre-coated with 1% general routine agarose (Sigma Aldrich ref# A9539). 
Microscope slides were laid onto an ice bed to let the agarose solidified. The slides were then 
immersed into the ice-cold lysis buffer (2.5 mM NaCl; 100 mM Na2EDTA; 10 mM Tris base; 10% 
DMSO and 1% Triton; pH 10) overnight at 4°C. For each animal 2 slides were made: one for the 
regular single gel electrophoresis assay and one for the formamidopyrimidine DNA glycosylase (FpG)-
modified comet assay. For the FpG-modified comet assay, following lysis, slides were washed three 
times 5 min with the FpG incubation buffer (Hepes 40 mM, KCl 0.1 M, EDTA 0.5 mM, bovine serum 
albumin 0.2 mg/mL; pH 8) at 4°C and then incubated for 30 min at 37°C with 5 U/mL of FpG (Sigma 
Aldrich ref#F3174) in the FpG incubation buffer. For the regular comet assay, slides were not treated 
the same way as for FpG-modified assay but without incubation with FpG enzyme. The slides were 
then immersed into the ice-cold alkaline electrophoresis buffer (300 mM NaOH; 1 mM Na2EDTA; 
pH>13) for 20 min and then submitted to electrophoresis for 40 min at 0,9 V/cm. At the end of the 
electrophoresis, slides were immersed into the neutralization buffer (Tris base 0.4 M; pH 7.5) for 15 
min at 4°C. Slides were then washed twice with ultrapure water for 5 min and dehydrated for 10 min 
into 96% ethanol before being dried at 45°C and stored in the dark at room temperature. For 
fluorescent microscopy analysis, slides were rehydrated 10 min with ultrapure water and then 
stained with propidium iodide 2.5 µg/mL in PBS. For each sample, 100 cells were analyzed using the 
Comet Assay IV software (Perceptive Instruments, Suffolk, UK) and the percentage of DNA in the tail 
of each comet was measured.  
 
2.1.1.6 Micronucleus assay 
Once fixed, the bone marrow slides were sent to the collaborating lab for staining and scoring.  
For staining, fixed bone marrow slides were sequentially incubated with: 
- filtered non diluted May-Grünwald stain (QUA-Med Polska) (3 min.) 
- gently wash with Sörensen’s Buffer (pH 7.2) 
- Giemsa (QUA-Med Polska) stain diluted with Sörensen’s Buffer (1:6, v/v; pH 7.2) (10 min.) 
- gently wash with Sörensen’s Buffer (pH 7.2) 
After washing and leaving for few minutes on absorbent paper, the slides are soaked in 95% for 5 
min. 
 
Only one scorer had scored all the slides from a whole study. The slides were first checked with low 
magnification for verification of cell morphology, spacing and staining. Then the slides were 
examined in the chosen area, systematically, in continuous fields counting each of the following cell 
types: 
- polychromatic erythrocytes (PCEs) distinguished by their bluish colour 
- mature erythrocytes (NCEs) distinguished by their pink colour 
- micronucleated polychromatic erythrocytes. 
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The proportion of PCEs among total (PCEs + NCEs) erythrocytes was determined for each animal by 
counting a total of at least 200 erythrocytes for bone marrow. 2000 PCEs/animal were scored for the 
presence of micronuclei.  
 
2.1.1.7 Histology 
Paraffin embedded tissue blocks from relevant SAS concentrations were analysed for histopathology 
by a subcontractor (Ricerca Biosciences SAS, France). 
 
 
 
2.1.2 RESULTS 
 
2.1.2.1 Broncho alveolar fluid cytology and biochemistry 
 
Changes in BAL fluid cell number and composition may be associated with a toxicological process and 
an inflammatory response (especially granulocytes influx). For all SAS, whatever the dose considered, 
a significant increase of influx of neutrophilic granulocytes was observed in BAL fluid from exposed 
animals with a dose-dependent trend (Figure 15). An increase of the total cell number was also 
noticed for all the SAS, but this change was not significant for the lowest dose of NM-200 and NM-
202. Main cell types observed in BAL fluid were macrophages and neutrophilic granulocytes, some 
lymphocytes were also observed but their frequency and number in SAS exposed animals were not 
significantly different from the control group (data not shown). In addition, in this study, the 
percentage of neutrophilic granulocytes in control (vehicle) group appears higher than that is usually 
obtained following a single intratracheal instillation and may be considered as an experimental 
artifact due to repeated animal exposure. 
 
Increase in lactate dehydrogenase (LDH), alkaline phosphatase (ALP) and N-acetyl-β-D-
glucosaminidase (NAG) activities and protein content are often signs of pulmonary toxicity following 
pulmonary exposure to particulate matter.  
For all SAS, a significant increase in the broncho-alveolar fluid of LDH and NAG activities was 
observed (Figure 16). A significant increase in the BAL fluid of protein content was only observed for 
NM-202 and NM-203 (highest dose) (Figure 17). No change in alkaline phosphatase (ALP) was 
however observed (Figure 17).  
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Figure 15: Cytology of bronchoalvolar lavage fluid from control and animals exposed by intratracheal 
instillation to SAS nanoparticles. . # Significantly different from the control (Dunnett’s test, p<0.05). 
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Figure 16: BAL fluid LDH (A) and NAG (B) activities in controls and rats exposed by intratracheal 
instillation to SAS.  # Significantly different from the control (Dunnett’s test, p<0.05). 
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Figure 17: BAL fluid ALP activity (A) and protein content (B) in controls and rats exposed by 
intratracheal instillation to SAS.    # Significantly different from the control (Dunnett’s test, p<0.05). 
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2.1.2.2 Comet assay 
 NM-200 
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Figure 18: DNA strand breaks assessed by the comet assay without (A) or with FpG (B) in the organs 
and tissues investigated from rats exposed by intratracheal instillation to NM-200  or by gavage to 
MMS or ENU (only for blood) (C).  # Significantly different from the control (Mann-Whitney test, 
p<0.05).  All data from MMS and ENU were significantly different from the control (Mann-Whitney 
test, p<0.05). 
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 NM-201 
 
 
 
A 
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Figure 19: DNA strand breaks assessed by the comet assay without (A) or with FpG (B) in the organs 
and tissues investigated from rats exposed by intratracheal instillation to NM-201 (A) or by gavage to 
MMS or ENU (only for blood) (C). All data from MMS and ENU were significantly different from the 
control (Mann-Whitney test, p<0.05). 
 
C 
 
   
Grant Agreement n° 2009 21 01 
 
 
The NANOGENOTOX Joint Action is co-funded by the Executive Agency 
 for Health and Consumers (Grant Agreement n°2009 21 01) under 
the European Union 2nd Health Programme. 
 
www.nanogenotox.eu 
48 
 
 NM-202 
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Figure 20: DNA strand breaks assessed by the comet assay without (A) or with FpG (B) in the organs 
and tissues investigated from rats exposed by intratracheal instillation to NM-202 (A) or by gavage to 
MMS or ENU (only for blood) (C). All data from MMS and ENU were significantly different from the 
control (Mann-Whitney test, p<0.05). 
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 NM-203 
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Figure 21: DNA strand breaks assessed by the comet assay in the organs and tissues investigated 
from rats exposed by intratracheal instillation to NM-203 or by gavage to MMS or ENU (only for 
blood) (B). All data from MMS and ENU were significantly different from the control (Mann-Whitney 
test, p<0.05). 
 
In conclusion, intratracheal instillation of SAS did not induce any significant increase of DNA 
damages in all the organs tested. In all the experiments performed, positive controls (MMS 
or ENU) always induced significant DNA strand breaks in the tissues analysed. 
 
 
2.1.2.3 Micronucleus assay 
 
No mutagenicity was observed in the bone marrow micronucleus assay irrespective of the SAS (Table 
9). 
C 
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Table 9: Genotoxicity (frequency of micronucleated Immature Erythrocytes) and toxicity (PCE/NCE 
ratio) induced in bone marrow by SAS following intratracheal instillation. Positive controls MMS and 
ENU were administered by gavage as described in the Material & Methods. PCE = polychromatic 
erythrocytes; NCE = normochromatic erythrocytes 
 
 
Genotoxicity Toxicity 
 
[mg/kg] Micronucleated 
Cells 
 Mean 
SD n SE PCE/NCE ratio Mean SD n SE 
  
  
NM 200 
0 0,00070 0,00045 5 0,00020 0,64 0,05 5 0,02 
3 0,00090 0,00042 5 0,00019 0,65 0,02 5 0,01 
6 0,00150 0,00050 5 0,00022 0,71 0,03 5 0,01 
12 0,00160 0,00042 5 0,00019 0,75 0,03 5 0,01 
MMS 25 0,00233 0,00029 3 0,00017 0,69 0,01 3 0,01 
ENU 25 0,00283 0,00029 3 0,00017 0,66 0,02 3 0,01 
NM 201 
0 0,00100 0,00041 4 0,00020 0,61 0,02 4 0,01 
3 0,00180 0,00027 5 0,00012 0,63 0,02 5 0,01 
6 0,00110 0,00042 5 0,00019 0,65 0,03 5 0,01 
12 0,00100 0,00061 5 0,00027 0,61 0,01 5 0,01 
MMS 25 0,00183 0,00058 3 0,00033 0,65 0,07 3 0,04 
ENU 25 0,00250 0,00050 3 0,00029 0,65 0,05 3 0,03 
NM 202 
0 0,00070 0,00057 5 0,00025 0,67 0,02 5 0,01 
3 0,00100 0,00050 5 0,00022 0,67 0,04 5 0,02 
6 0,00100 0,00035 5 0,00016 0,69 0,01 5 0,00 
12 0,00120 0,00045 5 0,00020 0,64 0,03 5 0,01 
MMS 25 0,00233 0,00076 3 0,00044 0,65 0,04 3 0,02 
ENU 25 0,00250 0,00050 3 0,00029 0,61 0,01 3 0,01 
NM 203 
0 0,00050 0,00035 5 0,00016 0,65 0,02 5 0,01 
3 0,00070 0,00045 5 0,00020 0,64 0,02 5 0,01 
6 0,00050 0,00050 5 0,00022 0,63 0,03 5 0,01 
12 0,00080 0,00045 5 0,00020 0,64 0,02 5 0,01 
MMS 25 0,00167 0,00029 3 0,00017 0,64 0,01 3 0,01 
ENU 25 0,00200 0,00050 3 0,00029 0,66 0,01 3 0,00 
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2.1.2.2 Histopathology findings 
 
Lung tissue from control and all the SAS exposed animals and liver, spleen and kidney from the 
control and exposed animals to the highest dose of SAS (i.e. 12 mg/kg) were sent for histopathology 
evaluation. Tissue slide analysis was done following Hematoxylin and eosin staining.  
 
The main findings were the following:  
 
 Lung: 
 
The incidence of minimal (and sometimes slight or moderate) subacute bronchiolitis/peribronchiolitis 
was slightly higher than controls dosed intratracheally in animals given SAS. The average severity of 
eosinophilic and/or pyknotic alveolar material was slightly higher than control in some groups given 
NM-201 or NM-203, although not with a clear dose-realtionship. The possibility cannot be excluded 
of an augmentation of these changes by these types of particle.  
Animals dosed intratracheally with vehicle or particle suspension had minimal or slight alveolar 
macrophages, granuloma, subacute bronchiolitis/peribronchiolitis or eosinophilic and/or pyknotic 
alveolar material, which were considered likely to have been due to the intratracheal dosing 
procedure. Acute perivascular and chronic pleural inflammatory cell infiltrates are seen 
spontaneously in laboratory rats and are not considered procedure-related. 
 
 
 L iver, spleen and kidney:  
Intratracheal administration of SAS suspensions did not induce any findings in these organs, since the 
findings observed were similar to those seen in controls and were of the types which are seen 
spontaneously in laboratory rats. 
 
2.2. Gavage 
2.2.1  MATERIAL AND METHODS 
 
2.2.1.1 Animals  
Each MN was tested separately. Experiments were conducted in male Sprague-dawley rats 6-8 weeks 
old (around 200 g). For each MN, the animals were divided into 5 groups with 5 animals per groups. 
Normal saline was used as a vehicle control whereas methylmethansulfonate  (MMS) was used as a 
positive control. 
The animals were treated via oral route (gavage) as three administrations at 0, 24 h and 45 h. In the 
case of MMS, the last dose was reduced to 80 mg/kg. 
Animals were sacrificed 3 h after the last administration. 
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2.2.1.2 Tissues collect and sample preparation 
Animals were anesthetized with intraperitoneal sublethal dose of pentobarbital (60 mg/kg). After 
collection of blood in heparin tube, the heart was perfused with 60 ml of cold perfusion medium 
(HBSS medium supplemented with EDTA 1 mM and Hepes 25 mM) at a flow of 10 ml/min. Organs 
were collected, rinsed with a grinding buffer (perfusion medium supplemented with 10 % DMSO) and 
kept on ice. For comet assay, liver and kidney were cut in small pieces and cells were mechanically 
isolated using a medimachine (5 sec in the grinding medium) whereas spleen cells were isolated by 
flushing small pieces with a pipette. Intestine and colon were rinsed with HBSS medium and cells 
were collected by scraping with a coverslip. Finally, bone marrow was collected from isolated femur 
using fetal calf serum. For histology, small pieces of liver, kidney, duodenum, colon and spleen were 
sampled, fixed in formaldehyde 4 % and embedded in paraffin. Only the sections from rats exposed 
to NM-203 were then sent for histology analysis. 
2.2.1.3 Comet assay  
The alkaline version of the Comet assay was performed following the recommendations of Tice et al. 
(Tice et al. 2000). FpG was used to detect oxidative DNA damage. 
Briefly, cells were embedded in 0.5 % of low melting point agarose and spread on microscope slides 
coated with agarose 0.8 % and precoated with agarose 1 %. After lysis for 1 h at 4° (buffer: 2.5 M 
NaCl, 100 mM Na2-EDTA, 10 mM Tris-HCl, pH10, 10 % DMSO and 1 % Triton X100), cells were washed 
2 x 5 min in FpG buffer (40 mM hepes, 100 mM KCl, 0.5 mM EDTA, 0.2 mg/ml BSA, pH8 ) . Slides were 
incubated with either FpG enzyme (3.6 U/slide) or buffer for 30 min at 37 °C. Slides were then 
immersed in an alkaline solution (NaOH 300 mM, Na2-EDTA 1 mM) in an electrophoretic tank for 20 
min to allow DNA unwinding and electrophoresis was realized at 300 mA and 25 V for 24 min. Slides 
were neutralized twice during 5 min with neutralization buffer before dehydrating in ethanol 95 °C 
for 5 min. For scoring, slides were stained with one drop of propidium iodide (PI) at 20 µg/ml. 
Analyses were performed with a fluorescence microscope using the Comet IV software. 50 nucleoids 
per slide with 2 slides per condition were scored. The median percentage Tail DNA (% Tail DNA) of 
100 nucleoids was chosen to evaluate the quantity of DNA damage and the mean of 5 animals was 
calculated. 
 
2.2.1.4 Micronucleus assays 
 Bone marrow micronucleus assay 
Smears were done by spreading a drop of cell suspension on a slide using a coverslip. After fixing 
with cold methanol, the smears were sent to scoring lab for staining and scoring. 
 Colon micronucleus assay 
The swiss roll technique was performed. The colon was sampled from the caecum to the rectum, cut 
longitudinally and washed with HBSS medium. After rolling up from the rectum to the caecum with 
the mucosa outwards, the tissue was fixed in formaldehyde 4 % and embedded in paraffin. Staining 
was performed using Schiff’s reagent, according to Feulgen method. First, longitudinal sections on 
slides were deparaffinized and dehydrated with toluene and ethanol. Then slides were stained using 
Schiff’s reagent followed by counterstaining with fast green and dehydration in ethanol (Figure 22). 
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For scoring, slides were mounted by adding DPX between slide and coverslip. Intact colon crypts 
were chosen for scoring at least 1000 cells per rat.  
 
 
Figure 22: Swiss rolls sections from colon of rats with Feulgen staining and Fast Green counterstain; 
magnification x400 (A) or x630 (B). 
 
2.2.1.5 LIpid peroxidation 
The lipid peroxidation was investigated through the dosage of malondialdehyde (MDA) in the plasma 
of rats orally exposed to SAS. 
 Principle 
Oxidative stress may impact all the cellularbiomolecules, especially the lipids. Polyinsaturated fatty 
acids (PUFA) from the cellular membranes are the main target of hydroxyl radical (•OH). This 
phenomenon of lipid peroxidation may trigger the formation of secondary metabolites such as 
malondialdehyde (MDA) which was shown to be cytotoxic and genotoxic. The level of MDA can be 
measured in biological fluids and was proposed as a biomarker of oxidative stress. In order to add 
complementary data to the FpG modified comet assay, we measured the levels of plasmatic MDA in 
the rats orally treated with SAS by gaseous chromatography coupled with mass spectrometry (GC-
MS) (Hewlet Packard-Agilent 6890 GC coupled with Agilent 5973 mass spectrometer). 
The method consists in derivating aldehydes into pentafluorobenzyloximes (O-PFB oximes) followed 
by an extraction and sylilation of hydroxyaldehydes to form trimethylsilyl (TMS) esters before GC/MS 
acquisition. Finally, molecules are identified and quantified using a calibration curve prepared with 
standard solution of MDA. 
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 Method:  
MDA was obtained by hydrolysis of TEP (1,1,3,3,-Tetraethoxypropane). TEP was dissolved in 0.1 N 
hydrochloric acid (HCl) and heated in boiling water for 5 min followed by a rapid cooling. The MDA 
stock solution was kept in the dark until used. Standard working solutions were prepared by diluting 
the stock solution in water in order to obtain solutions at 10, 25, 50, 100 and 200 ng/ml. 
50 µl of plasma from treated rats were added to 50 µl of water and spiked with 50 µl of tridecanal 
(internal standard). For the calibration curve, 50 µl of plasma from a rat control were spiked with 50 
µl of tridecanal and supplemented with 50 µl of the MDA dilutions (10, 25, 50, 100 and 200 ng/ml)  
Following derivatization with O-(2,3,4,5,6-Pentafluorolbenzyl)hydroxylamine hydrochloride 
(PFBHA.HCl ) for 1h, derivative was extracted with methanol followed by hexane. After shaking, the 
mixture was centrifuged at 3000 g for 5 min at 4°C. The upper layer of hexane was collected and 
dried. Then, the samples were suspended in 100 µl of hexane and 1 µl of sample was injected for 
GC/MS analysis using negative-ion chemical ionization. 
 
2.2.1.6 Histological analysis 
Samples of liver, kidney, duodenum, colon and spleen were fixed in formaldehyde 4 %. Following 
dehydration in ethanol then toluene, the samples were embedded in paraffin. Only the sections from 
rats exposed to NM-203 were then sent for analysis. 
 
2.2 RESULTS 
 
2.2.1 Comet assay 
 
The results are presented in the Figures 23 to 28. 
No DNA damage was observed after gavage with SAS irrespective of the MN and the organ 
investigated. 
Using FpG, no oxidative DNA damage was induced in the MN treated animals compared to 
the control.  
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 NM-200 
 
 
Figure 23: DNA strand breaks assessed by the comet assay without (A) or with FpG (B) in the organs 
and tissues investigated from rats exposed by gavage to NM-200. Results are expressed as mean ± SD 
with n=5 
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 NM-201 
 
 
Figure 24: DNA strand breaks assessed by the comet assay without (A) or with FpG (B) in the organs 
and tissues investigated from rats exposed by gavage to NM-201. Results are expressed as mean ± SD 
with n=5 
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 NM-202 
 
 
Figure 25: DNA strand breaks assessed by the comet assay without (A) or with FpG (B) in the organs 
and tissues investigated from rats exposed by gavage to NM-202. Results are expressed as mean ± SD 
with n=5 
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 NM-203 
 
 
Figure 26: DNA strand breaks assessed by the comet assay without (A) or with FpG (B) in the organs 
and tissues investigated from rats exposed by gavage to NM-203. Results are expressed as mean ± SD 
with n=5 
 
 
   
Grant Agreement n° 2009 21 01 
 
 
The NANOGENOTOX Joint Action is co-funded by the Executive Agency 
 for Health and Consumers (Grant Agreement n°2009 21 01) under 
the European Union 2nd Health Programme. 
 
www.nanogenotox.eu 
61 
Controls without FPG
 %
 t
a
il
 D
N
A
B
lo
od B
M
Li
ve
r
K
id
ne
y
S
pl
ee
n
C
ol
on
In
te
st
in
0
2
4
6
8
10
  
 
Controls with FPG
%
 t
a
il 
D
N
A
B
lo
od B
M
Li
ve
r
K
id
ne
y
S
pl
ee
n
C
ol
on
In
te
st
in
e
0
10
20
30
40
50
60
70
 
Figure 27: Variability of the comet assay results (%tail DNA) from control rats (n=20) without (A) or 
with FpG (B) in the organs and tissues investigated after gavage to SAS. 
 
 
 
 
   
Grant Agreement n° 2009 21 01 
 
 
The NANOGENOTOX Joint Action is co-funded by the Executive Agency 
 for Health and Consumers (Grant Agreement n°2009 21 01) under 
the European Union 2nd Health Programme. 
 
www.nanogenotox.eu 
62 
In the MMS treated animals, the DNA damage was very high, making the slides impossible to score 
irrespective of the organ. 
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Figure 28: Variability of the comet assay results (%tail DNA) from rats (n=20) treated with the 
chemical positive control MMS without FpG in the organs and tissues investigated after gavage with 
SAS. 
 
 
 
 
2.2.2 Micronucleus assay 
 Bone marrow 
No clastogenicity/aneugenicity was observed in bone marrow with the micronucleus assay 
irrespective of the SAS MN administered by gavage (Table 10). 
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Table 10: Genotoxicity (frequency of micronucleated Immature Erythrocytes) and toxicity (PCE/NCE 
ratio) induced by gavage with NM-200, -201, -202 and -203 in bone marrow. Positive control MMS 
was administered by gavage as described in the Material & Methods. PCE = polychromatic 
erythrocytes; NCE = normochromatic erythrocytes. 
 
 
    Genotoxicity Toxicity 
  [mg/kg] 
Micronucleated 
SD n SE 
PCE/NCE 
ratio 
Mean SD n SE 
Cells per 1000 IE 
     Mean 
NM 200 
0 3,00 1,17 5 0,52 0,59 0,22 5 0,10 
5 1,60 1,47 5 0,66 1,01 1,00 5 0,45 
10 2,00 1,17 5 0,52 0,72 0,48 5 0,21 
20 1,60 1,71 5 0,76 0,79 0,76 5 0,34 
MMS 100  36,80 17,28 5 7,73 0,30 0,25 5 0,11 
NM 201 
0 2,40 0,82 5 0,37 0,87 0,47 5 0,21 
5 2,40 0,96 5 0,43 1,88 0,87 5 0,39 
10 2,90 2,07 5 0,93 0,76 0,44 5 0,20 
20 2,20 1,48 5 0,66 0,92 0,71 5 0,32 
MMS 100  24,90 12,11 5 5,41 0,32 0,22 5 0,10 
NM 202 
0 2,20 0,57 5 0,25 3,61 2,14 5 0,96 
5 2,50 0,71 5 0,32 3,20 3,80 5 1,70 
10 3,30 1,64 5 0,73 2,07 2,97 5 1,33 
20 3,80 1,89 5 0,85 3,66 2,82 5 1,26 
MMS 100 30,30 8,31 5 3,72 0,51 0,19 5 0,08 
NM 203 
0 1,90 1,19 5 0,53 1,82 1,62 5 0,96 
5 2,30 1,64 5 0,73 1,74 1,10 5 1,70 
10 2,40 0,96 5 0,43 1,66 2,06 5 1,33 
20 2,10 1,08 5 0,48 0,84 0,50 5 1,26 
MMS 100  32,41 12,43 5 5,56 0,29 0,30 5 0,08 
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 Colon 
 
No induction of micronucleus formation in the colon was observed after gavage with NM-200 and -
201up to 20 mg/kg (x3). However, micronculeus formation was induced with NM-202 and -203 but 
the results were statistically significant only at the lowest dose (5 mg/kg (x3)) (Figure 29). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Micronucleus frequency scored from colon swiss rolls of rats treated with SAS by gavage. 
MMS was used as positive control. * For p ≤ 0.05; ** for p ≤ 0.01 and *** for p ≤ 0.001 with χ² test 
with Yate’s correction 
 
2.2.3 Lipid peroxidation 
 
Malondialdehyde (MDA) a product from lipid peroxidation commonly used as a marker of oxidative 
stress was measured in plasma samples collected from the animals treated by gavage. 
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No modification of the level of MDA in the plasma of SAS treated animals was observed, irrespective 
of the MN (Figure 30). 
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Figure 30: Level of MDA in plasma of rats treated by gavage with NM200, 201, 202 and 203. Mean of 
5 animals 
 
2.2.4 Histopathology 
 
No histological effects have been observed in liver, kidney, duodenum, colon and spleen 
from animals treated with NM 203 (5, 10 and 20 mg/kg). 
The three other SAS have not been investigated for histology. 
 
2.3 Intravenous administration of NM-203 
 
2.3.1 MATERIALS AND METHODS 
 
Seven-week old Sprague Dawley rats were purchased from Janvier and were exposed by intravenous 
injection to NM203 suspensions or vehicle 48, 24 and 3 hours before tissue collection.  
Three concentrations were tested 20; 10 and 5 mg/kg b.w. 
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For intravenous injection, animals were anesthetized with isoflurane and 330 µL of particle 
suspensions or vehicles were then administered per 100 g of b.w. through the tail vein using a 24G 
catheter. 
 
Tissue collection and dissociation were performed the same way as already described for the SAS 
intratracheal instillation study.  
Blood was also collected on in K2-EDTA- and Li heparin tubes for hematology and biochemistry 
respectively. 
Blood cell count was performed on a Scil Vetabc hematological counter. Leukocyte differential cell 
count was verified on blood smears stained with Grunwald Giemsa technique. 
 
Paraffin embedded tissue blocks from lung, liver, spleen and kidney from control and all NM203 
exposed animals were analyzed for histopathology by a subcontractor (Ricerca Biosciences SAS, 
France). 
 
 
2.3.2 RESULTS 
 
2.3.2.1 Toxicity 
 
The highest dose of intravenous NM-203 (20 mg/kg) induced animal death (3 out of 6). NM 203 
induced a dose dependent: 
  
- increase of spleen weight (Figure 31)  
- increase of liver damage as determined by liver enzymes (glutamic pyruvic transaminase 
(GPT) and glutamic oxaloacetic transaminase (GOT)) released into plasma (figure 32). 
- thrombocytopenia (Figure 34). 
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Figure 31: Spleen weight from controls and rats exposed by intravenous injection to NM-203.    
 # Significantly different from the control (Dunnett’s test, p<0.05). 
 
 
Figure 32: Plasma GOT and GPT activities in controls and rats exposed by intravenous injection to 
NM-203.   # Significantly different from the control (Dunnett’s test, p<0.05). 
 
2.3.2.1 Blood differential cell count 
 
Intravenous injection of NM-203 induced some modifications of the white blood cell formula and a 
dose-dependent thrombocytopenia. No change in red blood cell count was however detected (data 
not shown). 
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Figure 33: White blood cell differential cell count in controls and rats exposed by intravenous 
injection to NM-203. # Significantly different from the control (Dunnett’s test, p<0.05). Lympho: 
lymphocyte, Neutro: neutrophilic granulocyte, Eosino: eosinophilic granulocyte, Baso: basophilic 
granulocyte, Mono: monocyte. 
 
 
 
 
 
Figure 34: Thrombocytes in blood from controls and rats exposed by intravenous injection to NM-
203.  # Significantly different from the control (Dunnett’s test, p<0.05). 
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2.3.2.2 Comet assay 
 
MMS and/or ENU induced a significant increase of the percentage of tail DNA intensity in all the 
organs analysed. 
In both regular and FpG-modified comet assays, no increase of the percentage of tail DNA intensity 
was noticed in all the organs tested following intravenous NM-203 treatment (Figure 35). 
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Figure 35: DNA strand breaks assessed by the comet assay without (A) or with FpG (B) in the organs 
and tissues investigated from rats exposed by intravenous injection to NM-203 or by gavage to MMS 
or ENU (only for blood) (C). All data from MMS and ENU were significantly different from the control 
(Mann-Whitney test, p<0.05). 
 
 
 
2.3.2.3 Micronucleus assay 
 
Only a significant induction of micronucleus was obtained at the highest dose (20 mg/kg) (Table 11). 
However, the induction is weak and the results were obtained only from 3 animals due to the 
lethality induced at this concentration. 
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Table 11: Genotoxicity (frequency of micronucleated Immature Erythrocytes) and toxicity (PCE/NCE 
ratio) induced by intravenous NM-203 in bone marrow. Positive controls MMS and ENU were 
administered by gavage as described in the Material & Methods. 
 
 
 
Genotoxicity Toxicity 
[mg/kg] 
micronucleated 
cells 
Mean 
SD n SE 
PCE/NCE 
ratio 
Mean 
SD n SE 
NM 203 
0 0,00060 0,00042 5 0,00019 0,66 0,03 5 0,01 
5 0,00100 0,00035 5 0,00016 0,64 0,02 5 0,01 
10 0,00140 0,00042 5 0,00019 0,64 0,02 5 0,01 
20 0,00183 0,00076 3 0,00044 0,64 0,01 3 0,00 
MMS 25 0,00250 0,00050 3 0,00029 0,66 0,03 3 0,02 
ENU 25 0,00250 0,00050 3 0,00029 0,67 0,04 3 0,02 
 
 
 
2.3.2.4 Histopathology findings 
 
Lung, liver, spleen and kidney tissues from control and all NM-203 intravenously exposed 
animals were sent for histopathology evaluation. Tissue slide analysis was done following 
Hematoxylin and eosin staining.  
 
The main findings were the following:  
 
 Lung 
Intravenous administration of NM-203 did not induce any findings in the lungs. 
 
 Liver 
All animals dosed intravenously with NM-203 had multiple microgranulomas in the liver, 
which are considered to be due to NM-203. This is the type of lesion that would be expected 
from intravenous administration of a particle. This conclusion is reached despite the absence 
of a dose-response and despite the presence of single microgranulomas in three animals not 
given particle suspensions intravenously. Minimal microgranuloma formation is seen 
occasionally in untreated rats. There was a minimal increase in hepatocyte mitotic figures in 
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some of the animals with these microgranulomas; this is considered to be a secondary 
response of the hepatocytes to the heightened inflammatory state. 
 
 Spleen 
Minimal or slight increased macrophages in the red pulp was considered to have been 
induced by intravenous administration of all doses of NM-203, since it was present in most 
treated animals and had a dose-related severity pattern. This is the type of lesion that would 
be expected from intravenous administration of a particle. There was also an increased 
incidence of minimal neutrophil infiltrate and of pyknotic material in the splenic red pulp in 
groups given the medium or high dose of NM-203, which may indicate a minimal injurious 
effect of the particles in the spleen. Haematopoiesis is often seen in the spleen of rats and 
was not considered treatment-related. 
 
 Kidney 
Intravenous administration of the high dose of NM-203 may have induced minimal tubular 
dilatation with hyaline casts in the kidneys, although minimal findings such as these can 
occur in rats at this young age, as part of the development of spontaneous nephropathy.  
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In brief for SAS 
- Dose ranges: 
Instillation: 12, 6 and 3 mg/kg (x3)  
Gavage and intravenous (only NM-203): 20, 10 and 5 mg/kg (x3) 
  
- Comet assay: 
 No genotoxicity irrespective of the organ and the route of administration (instillation, gavage 
as well as iv administration only for NM-203) 
- Micronucleus assay: 
-  Bone marrow: 
 No mutagenicity irrespective of the route of administration 
 except after iv with NM-203 at the high dose (but no dose response, small increase as well as 
animal toxicity) 
-  Colon: 
 Mutagenicity for NM-202 and -203 only at the lowest dose 
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3) CNT 
 
3.1 MATERIAL AND METHODS 
 
3.1.1 Animals  
Young adult male OFA Sprague-Dawley rats (Charles River France origin, Saint-Germain-sur-
l’Arbresle; FRANCE) were used for the study. The period of acclimatisation was of at least 5 days. The 
animals received a clinical examination in order to retain only those which were healthy. 
The animals were identified by numbered ear rings. 
Body weights in male rats of the main assay were about 200 g. At the start of the main study, the 
weight range of animals did not exceed ± 20 % of the mean weight when compared to the vehicle 
group. Indeed, the weight homogeneity of the animals used in this test after random-distribution 
was checked, by comparing the mean weight in each treatment group with that in the control group 
using Student’s t test.  
The bedding consisted of dust-free, irradiated softwood pellets. 
The animals were dispatched in polypropylene cages by random-distribution. 
The cages were placed in a ventilated system in the animal room, which was ventilated 20 times per 
hour. A timer provides lighting 12 hours a day (8 a.m. - 8 p.m.) in all the animal room. The 
temperature in the ventilated animal cupboard was 22 ± 3 °C, and humidity was 55 ± 15 %. 
The animals were not fasted at the treatment time. Drinking water, softened by reverse osmosis and 
filtered on 0.20 µm membrane, was provided ad libitum. The feedstuff used was A04C irradiated 
from Safe. 
 
3.1.2 Nanoparticle preparation 
 Oral route:  
NM-400: dispersions at 0.64 mg/mL were prepared, i.e. function of the maximum of solubility 
of the nanomaterial 
NM-401 – NM-402 – NRCWE-006: dispersions at 2.56 mg/mL were prepared in accordance 
with the recommendations from WP4. 
 
 Endotracheal route: 
The highest concentration leading to a satisfactory dispersion and compatible with the route of 
exposure 
 NM-400: max initial concentration: 0.64 mg/mL 
 NM-401: max initial concentration: 0.32 mg/mL 
 NM-402: max initial concentration: 1.28 mg/mL 
 NRCWE-006: max initial concentration: 0.32 mg/mL 
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MNs were dispersed in sterile water (Fresenius) containing 0,05% of RSA and 0,5% of Ethanol 
according to the WP4 dispersion protocol. 
 
3.1.3 Treatments 
Rats were treated 3 times with the NMs by either oral or endotracheal route at different dose levels. 
Specifically, the animals were treated for 3 days at 24-hour interval. Three to six hours after the third 
treatment, the rats were deeply euthanized and cells from the selected target organs were isolated 
for both the micronucleus test and the comet assay. 
 
3.1.4 Tissue collection 
For tissue collection, animals were anesthetised with pentobarbital (60 mg/kg)  
 Colon:  
For NM-400, colon was opened and the internal side was scratched with a scrapper. Little pieces 
were prepared and put in a 50 µm-medicon with 1mL PBS for 10 seconds. Liquid was collected and 
medicon was rinsed with 1 mL of PBS. Liquid was added to 3 mL of PBS in a tube and then 
centrifugated at 1000 rpm for 5 minutes. Supernatant was removed and 3 mL of PBS were added. 
Cells were suspended and filtered through a 60 µm-filter. Finally, cells were enumerated in presence 
of Trypan blue. 
For the other MNs, colon was opened and the internal side was scratched with a scrapper. 8 mL of a 
mix collagenase/dispase were added and incubated at 37°C during 20 minutes. 0.8mL Fetal Bovine 
Serum was added and cells were suspended. Centrifugation was performed during 1000 rpm for 5 
minutes. Supernatant was pumped out and 4 mL of HBSS were added. Cells were enumerated in 
presence of Trypan blue. 
 
 Liver: 
For NM-400 (oral and endotracheal route), liver was cut in little pieces and then put in a 50 µm-
medicon and crushed for 5 seconds with 1 mL of PBS. Liquid was collected and medicon was washed 
with 1 mL of PBS. Liquid was added to 3 mL of PBS in a tube and then centrifugated at 400 rpm for 3 
minutes. Supernatant was removed and 3 mL of PBS were added. Cells were suspended and filtered 
through a 60 µm-filter. Finally, cells are enumerated in presence of Trypan blue. 
For the others MNs, liver was opened and gently cut with a scalpel in 5 mL of PBS. All the liquid was 
collected in a tube and cells were directly enumerated in presence of Trypan blue. 
 
 Spleen:  
A gentle incision was done with a scalpel and then scratched carefully in 5 mL of PBS. 500 µL of the 
liquid were collected and added to 10 mL of PBS. Counting was done in presence of Trypan blue. 
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 Kidney: 
The fibrous layer was taken off and kidney was cut in little pieces and then put in a 50 µm-medicon 
and crushed for 5 seconds with 1 mL of PBS. Liquid was collected and medicon was washed with 1 mL 
of PBS. Liquid was added to 3 mL of PBS in a tube and then centrifugated at 400 rpm for 3 minutes. 
Supernatant was removed and 3 mL of PBS were added. Cells were suspended and filtered through a 
60 µm-filter. Finally, cells were enumerated in presence of Trypan blue. 
 
 Lung:  
This organ was cut in little pieces and then put in a 50 µm-medicon and crushed for 5 secondes with 
1 mL of PBS. Liquid was collected and medicon was washed with 1 mL of PBS. Liquid was added to 3 
mL of PBS in a tube and then centrifugated at 400 rpm for 3 minutes. Supernatant was removed and 
3 mL of PBS were added. Cells were suspended and filtered through a 60 µm-filter. Finally, cells were 
enumerated in presence of Trypan blue. For the additional experiment, PBS was replaced by PBS + 
2% Fetal Calf Serum and previous to enumeration cells were filtered through a 150 µm-filter. 
 
3.1.5 Comet assay 
Before use, a volume of 85 µL of 0.8% of Normal Agarose (NA) was added on the microscope slide 
pre-layered with 1.5% of NA and then covered with a glass coverslip. Slides were placed at room 
temperature until the agarose layer hardened (3 to 5 minutes). Around 3 x 104 cells of the different 
doses tested were mixed with 75 µL of 0.5% of Low Melting Point Agarose (LMPA) kept at 37 °C and 
added on the microscope slide after gentlly sliding off the coverslip. The slides were then covered 
with a new glass coverslip, and were placed once again at room temperature for 3 to 5 minutes. 
Six slides were prepared for the comet assay: 2 for the regular single gel electrophoresis assay and 2 
for the formamidopyrimidine DNA glycosylase (FpG)-modified comet assay. Two other slides were 
prepared for the non-denaturating fast halo assay 
After the top layer of agarose has solidified, the glass coverslips were removed and the slides were 
immersed for at least 1 hour at + 4 °C in the dark in a lysing solution consisting of 2.5 M NaCl, 100 
mM EDTA, 10 mM Tris, pH 10, to which 1% Triton X-100 and 10% DMSO were freshly added (pH 
adjusted to 10 with NaOH). 
For the FpG-modified comet assay, following lysis, slides were washed two times 5 min with the FpG 
incubation buffer (Hepes 40 mM, KCl 0.1 M, EDTA 0.5 mM, bovine serum albumin 0.2 mg/mL; pH 8) 
at room temperature and then incubated for 35 min at 37°C with 0.6 U/mL of FpG (Sigma Aldrich ref 
F3174) in the FpG incubation buffer. For the standard comet assay, slides were not treated with FpG. 
 
After this incubation period, the slides were then removed and placed on a horizontal gel 
electrophoresis unit and the unit filled with freshly prepared alkaline buffer (1 mM EDTA and 300 
mM NaOH, pH > 13) to around 0.25 cm above the slides. In order to avoid excessive variation across 
the groups during each electrophoretic run, only one of the replicate slides was processed in each 
run for each animal (DNA – unwinding and electrophoresis). The cells were exposed to the alkali for 
20 minutes to allow the DNA unwinding, and expression of single-strand breaks and alkali-labile sites. 
Next, electrophoresis was conducted for 20 minutes at 0-4°C by applying an electric current of 0.7 V / 
cm (25 V / 300 mA). All these steps were conducted protected from daylight to prevent the 
occurrence of additional DNA damage. After electrophoresis at pH >13, the slides were neutralized 
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twice for 5 minutes with 0.4 M Tris (pH 7.5) and the DNA was exposed for 5 minutes to absolute 
ethanol in order to preserve all the comet assay slides. Subsequently, the slides were airdried and 
then stored at room temperature until they were scored for DNA migration. 
Just prior to scoring, the DNA was stained using propidium iodide (final concentration of 20 µg/mL in 
distilled water; 25 µL/slide). 
Slides were examined with a 200 x magnification, using a fluorescent microscope (Leica 
Microsystems SAS - DM 2000, Heerbrugg, Switzerland), equipped with an excitation filter of 515-560 
nm and a barrier filter of 590 nm, connected through a gated monochrome CCD IEEE1394 FireWire 
video camera (Allied Vision Technologies), to the Comet Assay IV Image Analysis System, version 4.11 
with Windows XP Pro Software (Perceptive Instruments Ltd, Suffolk, UK). 
6 slides were prepared for each animal and each organ, with 4 animals per group. 100 cells per slide 
were randomly scored, i.e. 200 cells per animal (800 analysed cells per group).  
 
For the Fast Halo Assay, the slides were immersed in the lysis solution at pH 10.1, for 10 minutes at + 
4 °C in the dark. The slides were then rinsed in PBS for less than 30 seconds and neutralized for 15 
minutes in PBS (pH 7.4) containing 0.1 mg/mL RNase. The DNA was then rinsed in distilled water and 
exposed for 5 minutes to absolute ethanol in order to preserve all the halo assay slides. 
Subsequently, the slides were airdried and then stored at room temperature until they were scored 
for the presence of halos. 
Just prior to scoring, the DNA was stained using propidium iodide (final concentration of 20 µg/mL in 
distilled water; 25 µL/slide). 
 
In order to quantify the test item effects on DNA, the following statistical analysis strategy was 
applied, using the statistical software Stat view®, version 5. 
 
As the median of percentage of DNA in tail and other tail parameters do not follow a Gaussian 
distribution (E. Bauer et al., 1998), the non-parametric, one-way Kruskall-Wallis test was performed. 
This method is based on the analysis of variance by ranks for testing equality of population medians 
among groups, in order to display a possible dose-response relationship. 
The non-parametric Mann-Whitney U-test was applied to compare each of the doses tested with the 
vehicle control in order to determine statistical significance of differences in group median values 
between each group versus the vehicle control. This test was also used to compare vehicle control 
and positive control to determine acceptable criteria of a valid test. 
 
3.1.6 Micronucleus test on bone marrow 
At the sampling time, the femurs were removed and the bone marrows were extracted with fetal calf 
serum (1 mL per animal). The cell suspensions were centrifuged for 5 minutes at 1000 rpm. The 
supernatants were removed. The centrifugate was spread on slides. The smears were stained using a 
technique, derived from the May Grunwald Giemsa technique which makes it possible to distinguish 
between polychromatic (PCE) and normochromatic erythrocytes (NCE): PCE are purple whereas NCE 
are red. 
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After blind coding the slides by a person not involved in the study, two slides per animal were read 
by two independent operators; for each animal, the number of polychromatic erythrocytes having 
one or more Howell-Jolly bodies (micronuclei) was determined from the microscopic examination of 
2000 polychromatic erythrocytes. As divergence was noted, 2000 new polychromatic erythrocytes 
were examined. The retained value was the mean of all readings. 
The polychromatic/normochromatic erythrocyte ratio was determined from the microscopic 
examination of 1000 erythrocytes per animal. 
 
The statistical comparison for the polychromatic/normochromatic erythrocyte ratio was performed 
using Student's t test. 
Statistical analysis was performed for micronucleated PCE number using the Chi² test.  
 
3.1.7 Micronucleus test on colon 
Micronucleus test on colon was performed according to the protocol already described for TiO2 and 
SAS. 
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3.2 RESULTS 
3.2.1 Intratracheal instillation 
3.2.1.1 Comet assay 
 NM-400 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Comet assay with NM-400 without (A) or with FpG (B) 
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Comments without FpG 
As no satisfactory DNA migration was noted in the spleen, the results were invalidated. 
A statistically significant increase in the percentage of DNA in tail was noted in kidney at the highest 
dose of 0.48 mg/kg/day (x3). 
Regarding the results noted for the positive control, MMS, in the liver, the results were considered 
as biologically significant (high inter‐animals heterogeneity). 
 
 
With FPG 
As no satisfactory DNA migration was noted in the spleen, the results were invalidated. 
No statistically significant increase in the percentage of DNA in tail was noted whatever the organ 
analyzed and the dose tested. 
 
 
 
 
Conclusion NM-400 - Instillation 
No statistically significant increase in the percentage of tail DNA with or without FpG, except in the 
kidney at the highest dose of 0.48 mg/kg/day (x3), in the presence of FpG. 
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 NM-401 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: Comet assay with NM-401 without (A) or with FpG (B) 
 
Comments without FpG 
The quality of the slides prepared for the lung was unsatisfactory and too few cells were analysable 
in all groups. The results were thus invalidated.  
Statistically significant increases in the percentage of DNA in tail were noted in the spleen at the 
lowest dose of 0.1 mg/kg/day (x3) and in the BAL at 0.1 and 0.4 mg/kg/day (x3). 
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Comments with FpG 
Statistically significant increases in the percentage of DNA in tail were noted in the spleen at the 
lowest dose of 0.1 mg/kg/day (x3), and in the kidney at 0.1 and 0.2 mg/kg/day (x3). 
Regarding the results for the lung and the BAL, they had to be invalidated. 
Therefore, an additional experiment was carried out to investigate the NM 401 effect only on those 
organs with some modification for lung cell collection (see Material & Methods section). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38: Comet assay with NM-401, additional experiment without (A) or with FpG (B) 
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Statistically significant increases in the percentage of DNA in tail were noticed in lung at the lowest 
dose of 0.1 mg/kg/day (x3), in the absence of FpG only. 
 
 
In order to verify if any effect could be observed with lower doses in lung, a third assay was 
performed only on lung with a dose range between 0.05 and 0.2 mg/kg/day. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: Comet assay with NM-401, additional experiment on lung with lower doses 
exposure without (A) or with FpG (B) 
 
No statistically significant increase in the percentage of DNA in tail was noted at the doses tested 
from 0.05 to 0.2 mg/kg/day (x2), either in the absence or in the presence of FpG. 
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Conclusion NM-401 – Instillation 
The manufactured nanomaterial NM-401 induced statistically significant increase in the percentage 
of tail DNA in the spleen both with or without FpG at the lowest dose of 0.1 mg/kg/day (x3) and in 
the kidney at the 2 lowest doses of 0.1 and 0.2 mg/kg/day (x3), in the presence of FpG but also in the 
lung at the lowest dose only without FpG as shown in the 2nd assay described above. 
 
 
 NM-402 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40: Comet assay with NM-402 – endotracheal route – without (A) or with FpG (B) 
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Comments without FpG 
No statistically significant increase in the percentage of tail DNA was noticed irrespective of the 
organ and the dose tested. 
 
A decrease in the percentage of DNA in tail was noticed, in the liver at 0.8 mg/kg/day (x3) and in the 
lung at 1.6 mg/kg/day (x3). They are devoid of genotoxic hazard 
 
Numerous ghost cells in all organs were observed from the analysis of the slides of the positive 
control, MMS. 
 
 
 
Comments with FpG 
Statistically significant increases in the percentage of DNA in tail were noted in the kidney at 0.4 and 
0.8 mg/kg/day (x3). 
 
NB: A decrease in the percentage of DNA in tail was noted, in the lung at 1.6 mg/kg/day (x3). It is 
devoid of genotoxic hazard. 
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 NRCWE-006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: Comet assay with NRCWE-006 without (A) or with FpG (B) 
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Comments without FpG 
The results for the kidney of rats treated with 0.1 mg/kg/day (x3) demonstrated a statistically 
significant increase in DNA migration. However, slides from 2 animals out of 4 were actually 
analysed. Results must be taken with caution and considered as equivocal  
 
An increase in the percentage of DNA in tail was noted in the kidney and in the BAL at 0.1 mg/kg/day 
(x3), and in the lung at 0.2 mg/kg/day (x3).  
 
NB: Decreases in the percentage of DNA in tail were noted, in the BAL at 0.2 and 0.4 mg/kg/day (x3). 
They are devoid of genotoxic hazard. 
 
Regarding the results obtained with the positive control, MMS, in the kidney, the lung and the BAL, 
they were considered as  biologically significant. 
Otherwise, the slides of the liver showed numerous ghost cells. 
 
 
 
 
Comments with FpG 
As the quality of the slides was unsatisfactory in the kidney, the lung and the BAL, the results were 
invalidated. 
 
No statistically significant increase in the percentage of tail DNA was noticed irrespective of the 
organ and the dose tested, 
A decrease in the percentage of DNA in tail was noticed, in liver at 0.1 mg/kg/day (x3). It is devoid of 
genotoxic hazard. 
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3.2.1.2 Micronucleus assay 
 
 NM-400 
 
PCE / NCE ratio 
The ratio of polychromatic (PCE) to normochromatic erythrocytes (NCE) was established at each dose 
level. No statistically significant decrease in the ratio PCE to NCE was noted in the 3 NM400 
treatment groups when compared to the negative control group. In consequence, no proof of 
systemic exposure was evidenced (Table 12).  
 
Frequency of micronucleated PCE 
Regarding the frequency of micronucleated polychromatic erythrocytes, no statistically significant 
increase in the frequencies of micronucleated polychromatic erythrocytes was found in the animals 
treated with NM400 at any dose when compared with the control group (Table 12). 
 
Therefore, NM400 was considered as not genotoxic under these experimental conditions. 
 
Table 12: Micronucleus test on bone marrow with NM-400 – endotracheal route  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLING TIME
(3-6 H after TEST ITEM
last treatment*)
DOSES in
mg/kg/day (x3)
0.05% RSA 0 0.95 +/- 0.34 0.80 +/- 0.57
Cyclophosphamide
POSITIVE 10 mL/kg 0.72N.S. 0.19 N.S. 6.00 +/- 1.17 39.9 <0.001
25 mg/kg/day (x1)
1.02 +/- 0.15 N.S. 1.10 +/- 0.74 0.474 N.S.
NM 400 0.98 +/- 0.21 N.S. 0.50 +/- 0.35 0.693 N.S.
0.99 +/- 0.17 N.S. 0.60 +/- 0.42 0.286 N.S.
N.S.: Non-significant at the threshold of p=0.05
PCE: Polychromatic erythocytes
NCE: Normochromatic erythocytes
SD: Standard Deviation
Student's 
t Test                  
(p)
p
0.48
Mean +/- SD
MICRONUCLEI FOR 1000 PCE
Chi² test

PCE / NCE RATIO
Mean +/- SD
* except for positive control: 24h after unique treatment
0.12
0.24
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 NM-401 
 
PCE / NCE ratio 
The ratio of polychromatic (PCE) to normochromatic erythrocytes (NCE) was established at each dose 
level. No statistically significant decrease in the ratio PCE to NCE was noted in the 3 NM401 
treatment groups when compared to the negative control group. In consequence, no proof of 
systemic exposure was evidenced (Table 13). 
 
Frequency of micronucleated PCE 
Regarding the frequency of micronucleated polychromatic erythrocytes, no statistically significant 
increase in the frequencies of micronucleated polychromatic erythrocytes was found in the animals 
treated with NM401 at any dose when compared with the control group (Table 13). 
 
Therefore, NM401 was considered as not genotoxic under these experimental conditions. 
 
Table 13: Micronucleus test on bone marrow with NM-401 – endotracheal route  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLING TIME
(3-6 H after TEST ITEM
last treatment*)
DOSES in
mg/kg/day (x3)
0.05% RSA 0 1.05 +/- 0.51 0.90 +/- 0.74
Cyclophosphamide
POSITIVE 10 mL/kg 0.43N.S. 0.08 <0.05 7.60 +/- 4.41 53.037 <0.001
25 mg/kg/day (x1)
1.08 +/- 0.16 N.S. 0.80 +/- 0.67 0.059 N.S.
NM 401 0.85 +/- 0.16 N.S. 0.50 +/- 0.50 1.144 N.S.
0.82 +/- 0.17 N.S. 0.60 +/- 0.55 0.6 N.S.
N.S.: Non-significant at the threshold of p=0.05
PCE: Polychromatic erythocytes
NCE: Normochromatic erythocytes
SD: Standard Deviation
* except for positive control: 24h after unique treatment
0.1
0.2
0.4
Mean +/- SD
MICRONUCLEI FOR 1000 PCE
Chi² test

PCE / NCE RATIO
Mean +/- SD
Student's 
t Test                  
(p)
p
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 NM-402 
 
PCE / NCE ratio 
The ratio of polychromatic (PCE) to normochromatic erythrocytes (NCE) was established at each dose 
level. No statistically significant decrease in the ratio PCE to NCE was noted in the 3 NM-402 
treatment groups when compared to the negative control group. In consequence, no proof of 
systemic exposure was evidenced (Table 14).  
 
Frequency of micronucleated PCE 
Regarding the frequency of micronucleated polychromatic erythrocytes, no statistically significant 
increase in the frequencies of micronucleated polychromatic erythrocytes was found in the animals 
treated with NM402 at any dose when compared with the control group (Table 14). 
 
Therefore, NM402 was considered as not genotoxic under these experimental conditions. 
 
Table 14: Micronucleus test on bone marrow with NM-402 – endotracheal route  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLING TIME
(3-6 H after TEST ITEM
last treatment*)
DOSES in
mg/kg/day (x3)
0.05% RSA 0 0.92 +/- 0.29 0.50 +/- 0.35
Cyclophosphamide
POSITIVE 10 mL/kg 0.63 +/- 0.11 N.S. 19.40 +/- 5.89 181.31 <0.001
25 mg/kg/day (x1)
0.88 +/- 0.14 N.S. 0.30 +/- 0.45 0.13 N.S.
NM 402 1.02 +/- 0.28 N.S. 0.60 +/- 0.42 0.09 N.S.
1.00 +/- 0.19 N.S. 0.30 +/- 0.45 0.13 N.S.
N.S.: Non-significant at the threshold of p=0.05
PCE: Polychromatic erythocytes
NCE: Normochromatic erythocytes
SD: Standard Deviation
Student's 
t Test                  
(p)
p
1.6
Mean +/- SD
MICRONUCLEI FOR 1000 PCE
Chi² test

PCE / NCE RATIO
Mean +/- SD
* except for positive control: 24h after unique treatment
0.4
0.8
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 NRCWE-006 
 
PCE / NCE ratio 
The ratio of polychromatic (PCE) to normochromatic erythrocytes (NCE) was established at each dose 
level. No statistically significant decrease in the ratio PCE to NCE was noted in the 3 NRCWE-006 
treatment groups when compared to the negative control group. In consequence, no proof of 
systemic exposure was evidenced (Table 15).  
 
Frequency of micronucleated PCE 
Regarding the frequency of micronucleated polychromatic erythrocytes, no statistically significant 
increase in the frequencies of micronucleated polychromatic erythrocytes was found in the animals 
treated with NRCWE-006 at any dose when compared with the control group (Table 15). 
 
Therefore, NRCWE-006 was considered as not genotoxic under these experimental conditions. 
 
Table 15: Micronucleus test on bone marrow with NRCWE-006 – endotracheal route  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLING TIME
(3-6 H after TEST ITEM
last treatment*)
DOSES in
mg/kg/day (x3)
0.05% RSA 0 1.11 +/- 0.31 0.80 +/- 0.84
Cyclophosphamide
POSITIVE 10 mL/kg 0.75N.S. 0.39 N.S. 14.70 +/- 8.42 125.625 <0.001
25 mg/kg/day (x1)
1.03 +/- 0.44 N.S. 0.50 +/- 0.50 0.693 N.S.
NM 401 0.83 +/- 0.34 N.S. 0.50 +/- 0.35 0.693 N.S.
0.90 +/- 0.24 N.S. 0.70 +/- 0.76 0.067 N.S.
N.S.: Non-significant at the threshold of p=0.05
PCE: Polychromatic erythocytes
NCE: Normochromatic erythocytes
SD: Standard Deviation
Student's 
t Test                  
(p)
p
0.4
Mean +/- SD
MICRONUCLEI FOR 1000 PCE
Chi² test

PCE / NCE RATIO
Mean +/- SD
* except for positive control: 24h after unique treatment
0.1
0.2
NRCWE 
006 
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3.2.2 Gavage 
 
3.2.2.1 Comet assay 
 
 NM-400 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42: Comet assay with NM-400 without (A) or with FpG (B) 
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Comments without FpG 
The slides for spleen from only 2 animals in negative control were analysed (Failure in DNA 
migration). Moreover, great inter-animals heterogeneity was noted. Results must be taken with 
caution and considered as equivocal. 
Otherwise, no statistically significant increase in the percentage of DNA in tail was noted whatever 
the organ analysed and the dose tested. 
 
 
The results obtained with MMS demonstrated biological significance for all organs (high inter-animals 
heterogeneity). 
 
Comments with FpG 
A statistically significant increase in the percentage of DNA in tail was noted in kidney at the lowest 
dose of 3.2 mg/kg/day (x3). 
 
 
 
Conclusion NM-400 - Oral route 
No statistically significant increase in the percentage of tail DNA with or without FpG, except in the 
kidney at the lowest dose of 3.2 mg/kg/day (x3), in the presence of FpG. 
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 NM-401 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43: Comet assay with NM-401 without (A) or with FpG (B) 
FpG-
0
10
20
30
40
50
60
70
80
90
0 12.8 25.6 51.2 MMS
doses in mg/kg/day (x3)
%
 o
f 
D
N
A
 i
n
 t
a
il
Colon
Liver
Spleen
Kidney
*
*
*
FpG+
0
10
20
30
40
50
60
70
80
90
0 12.8 25.6 51.2
Doses in mg/kg/day (x3)
%
 o
f 
D
N
A
 i
n
 t
a
il Colon
Liver
Spleen
Kidney
B 
 A  
A 
 A  
 
   
Grant Agreement n° 2009 21 01 
 
 
The NANOGENOTOX Joint Action is co-funded by the Executive Agency 
 for Health and Consumers (Grant Agreement n°2009 21 01) under 
the European Union 2nd Health Programme. 
 
www.nanogenotox.eu 
95 
 
Comments without FpG 
A statistically significant response observed at 25.6 mg/kg/day (x3) in the kidney. However, it is 
noteworthy that for one series of slides, unsatisfactory DNA migration was noted (no data for this 
series). Results must be taken with caution, and considered as equivocal 
Otherwise, a statistically significant increase in the percentage of DNA in tail was noted in the liver at 
the intermediary dose of 25.6 µg/kg/day (x3). 
The results obtained with the positive control (MMS) in the spleen demonstrated biological 
significance (high inter-animals heterogeneity). 
 
Comments with FpG 
The quality of slides prepared for the kidney and the colon was unsatisfactory. The results were thus 
invalidated. 
 
No statistically significant increase in the percentage of DNA in tail was noted whatever the organ 
analysed and the dose tested. 
 
 
Conclusion NM-401 - Oral route 
Statistically significant increases in the percentage of tail DNA were noted in liver and kidney at the 
intermediary dose of 25.6 µg/kg/day (x3) only in absence of FpG. This effect was considered as 
equivocal in the kidney 
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 NM-402 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44:  Comet assay with NM-402 without (A) or with FpG (B) 
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Comments without FpG 
The quality of slides prepared for the colon was unsatisfactory and too few cells were analysable in 
all groups. The results were thus invalidated. 
No statistically significant increase in the percentage of DNA in tail was noted whatever the organ 
analysed and the dose tested. 
 
Decreases in the percentage of DNA in tail were noted. They are devoid of genotoxic hazard. 
 
Regarding the results obtained with the positive control, MMS, in the liver, they were considered as 
biologically significant. 
Otherwise, at the analysis of the slides of the kidney and the spleen, it was noted too numerous 
ghost cells, and the results were invalidated. 
  
Comments with FpG 
The quality of slides prepared for the kidney, the spleen and the colon was unsatisfactory. The 
results were thus invalidated. 
 
No statistically significant increase in the percentage of DNA in tail was noted whatever the organ 
analysed and the dose tested.  
 
  
 
Conclusion NM-402 - Oral route 
No statistically significant increase in the percentage of DNA in tail was noted whatever the organ 
analysed and the dose tested, either in the absence or in the presence of FpG. 
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 NRCWE-006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45: Comet assay with NRCWE-006 without (A) or with FpG (B) 
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Comments without FpG 
No statistically significant increase in the percentage of DNA in tail was noted whatever the organ 
analysed and the dose tested. 
 
Decreases in the percentage of DNA in tail were noted. They are devoid of genotoxic hazard. 
 
Regarding the results obtained with the positive control, MMS, in the liver, they were considered as 
biologically significant. 
Otherwise, at the analysis of the slides of the colon, it was noted too numerous ghost cells. 
 
 
Comments with FpG 
No statistically significant increase in the percentage of DNA in tail was noted whatever the organ 
analysed and the dose tested.  
 
Decreases in the percentage of DNA in tail were noted. They are devoid of genotoxic hazard. 
 
Conclusion NRCWE-006 - Oral route 
No statistically significant increase in the percentage of DNA in tail was noted whatever the organ 
analysed and the dose tested, either in the absence or in the presence of FpG. 
 
 
3.2.1.2 Bone marrow micronucleus assay 
 
 NM-400 
 
PCE / NCE ratio 
The ratio of polychromatic (PCE) to normochromatic erythrocytes (NCE) was established at each dose 
level. No statistically significant decrease in the ratio PCE to NCE was noted in the 3 NM400 
treatment groups when compared to the negative control group. In consequence, no proof of 
systemic exposure was evidenced (Table 16).  
 
Frequency of micronucleated PCE 
Regarding the frequency of micronucleated polychromatic erythrocytes, no statistically significant 
increase in the frequencies of micronucleated polychromatic erythrocytes was found in the animals 
treated with NM-400 at any dose when compared with the control group (Table 16). 
 
Therefore, NM-400 was considered as not genotoxic under these experimental conditions. 
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Table 16: Micronucleus test on bone marrow with NM-400  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 NM-401 
 
PCE / NCE ratio 
The ratio of polychromatic (PCE) to normochromatic erythrocytes (NCE) was established at each dose 
level. No statistically significant decrease in the ratio PCE to NCE was noted in the 3 NM-401 
treatment groups when compared to the negative control group. In consequence, no proof of 
systemic exposure was evidenced (Table 17).  
 
Frequency of micronucleated PCE 
Regarding the frequency of micronucleated polychromatic erythrocytes, no statistically significant 
increase in the frequencies of micronucleated polychromatic erythrocytes was found in the animals 
treated with NM-401 at any dose when compared with the control group (Table 17). 
 
Therefore, NM-401 was considered as not genotoxic under these experimental conditions. 
 
SAMPLING TIME
(3-6 H after TEST ITEM
last treatment*)
DOSES in
mg/kg/day (x3)
0.05% RSA 0 0.57 +/- 0.24 2.40 +/- 0.82
Cyclophosphamide
POSITIVE 10 mL/kg 0.37 +/- 0.20 N.S. 46.70 +/- 11.51 409.752 <0.001
25 mg/kg/day (x1)
0.43 +/- 0.13 N.S. 3.60 +/- 2.25 2.407 N.S.
NM 400 0.74 +/- 0.39 N.S. 2.60 +/- 0.65 0.08 N.S.
0.64 +/- 0.43 N.S. 2.00 +/- 0.79 0.364 N.S.
N.S.: Non-significant at the threshold of p=0.05
PCE: Polychromatic erythocytes
NCE: Normochromatic erythocytes
SD: Standard Deviation
* except for positive control: 24h after unique treatment
3.2
6.4
12.8
Mean +/- SD
MICRONUCLEI FOR 1000 PCE
Chi² test

PCE / NCE RATIO
Mean +/- SD
Student's 
t Test                  
(p)
p
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Table 17: Micronucleus test on bone marrow with NM-401 – Oral route  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 NM-402 
 
PCE / NCE ratio 
The ratio of polychromatic (PCE) to normochromatic erythrocytes (NCE) was established at each dose 
level. No statistically significant decrease in the ratio PCE to NCE was noted in the 3 NM-402 
treatment groups when compared to the negative control group. In consequence, no proof of 
systemic exposure was evidenced (Table 18).  
 
 
Frequency of micronucleated PCE 
Regarding the frequency of micronucleated polychromatic erythrocytes, a statistically significant 
increase in the frequencies of micronucleated polychromatic erythrocytes was found in the animals 
treated with NM-402 at the highest dose (51.2 mg/kg) when compared with the control group (Table 
18). 
However, the number of micronucleated cells was within the interval of historical data for negative 
control obtained in our lab (i.e. 0-3). Therefore, NM-402 was considered as not genotoxic under 
these experimental conditions. 
SAMPLING TIME
(3-6 H after TEST ITEM
last treatment*)
DOSES in
mg/kg/day (x3)
0.05% RSA 0 0.96 +/- 0.11 2.60 +/- 0.89
Cyclophosphamide
POSITIVE 10 mL/kg 0.34 +/- 0.07 <0.001 35.20 +/- 8.79 286.57 <0.001
25 mg/kg/day (x1)
1.03 +/- 0.20 N.S. 3.50 +/- 1.12 1.332 N.S.
NM 401 1.90 +/- 2.14 N.S. 1.80 +/- 0.91 1.458 N.S.
1.05 +/- 0.17 N.S. 2.20 +/- 0.76 0.334 N.S.
N.S.: Non-significant at the threshold of p=0.05
PCE: Polychromatic erythocytes
NCE: Normochromatic erythocytes
SD: Standard Deviation
Student's 
t Test                  
(p)
p
51.2
Mean +/- SD
MICRONUCLEI FOR 1000 PCE
Chi² test

PCE / NCE RATIO
Mean +/- SD
* except for positive control: 24h after unique treatment
12.8
25.6
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Table 18: Micronucleus test on bone marrow with NM-402 – Oral route 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 NRCWE-006 
 
PCE / NCE ratio 
The ratio of polychromatic (PCE) to normochromatic erythrocytes (NCE) was established at each dose 
level. No statistically significant decrease in the ratio PCE to NCE was noted in the 3 NRCWE-006 
treatment groups when compared to the negative control group. In consequence, no proof of 
systemic exposure was evidenced (Table 19).  
 
Frequency of micronucleated PCE 
Regarding the frequency of micronucleated polychromatic erythrocytes, no statistically significant 
increase in the frequencies of micronucleated polychromatic erythrocytes was found in the animals 
treated with NRCWE-006 at any dose when compared with the control group (Table 19). 
 
Therefore, NRCWE-006 was considered as not genotoxic under these experimental conditions. 
 
 
 
 
SAMPLING TIME
(3-6 H after TEST ITEM
last treatment*)
DOSES in
mg/kg/day (x3)
0.05% RSA 0 0.82 +/- 0.16 1.00 +/- 0.94
Cyclophosphamide
POSITIVE 10 mL/kg 0.51 +/- 0.19 <0.05 22.20 +/- 6.96 195.998 <0.001
25 mg/kg/day (x1)
1.74 +/- 0.53 <0.01 2.10 +/- 0.65 3.909 <0.05
NM 402 1.32 +/- 0.34 <0.05 2.00 +/- 0.79 3.338 N.S.
1.06 +/- 0.49 N.S. 1.90 +/- 1.24 2.797 N.S.
N.S.: Non-significant at the threshold of p=0.05
PCE: Polychromatic erythocytes
NCE: Normochromatic erythocytes
SD: Standard Deviation
* except for positive control: 24h after unique treatment
12.8
25.6
51.2
Mean +/- SD
MICRONUCLEI FOR 1000 PCE
Chi² test

PCE / NCE RATIO
Mean +/- SD
Student's 
t Test                  
(p)
p
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Table 19: Micronucleus test on bone marrow with NRCWE 006 – Oral route  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
SAMPLING TIME
(3-6 H after TEST ITEM
last treatment*)
DOSES in
mg/kg/day (x3)
0.05% RSA 0 0.99 +/- 0.22 1.40 +/- 0.74
Cyclophosphamide
POSITIVE 10 mL/kg 0.42 +/- 0.12 <0.001 4.70 +/- 2.71 17.907 <0.001
25 mg/kg/day (x1)
1.52 +/- 0.61 N.S. 0.60 +/- 0.65 3.203 N.S.
NRCWE 006 1.30 +/- 0.30 N.S. 0.80 +/- 0.67 1.638 N.S.
0.85 +/- 0.48 N.S. 1.40 +/- 0.55 0 N.S.
N.S.: Non-significant at the threshold of p=0.05
PCE: Polychromatic erythocytes
NCE: Normochromatic erythocytes
SD: Standard Deviation
Student's 
t Test                  
(p)
p
51.2
Mean +/- SD
MICRONUCLEI FOR 1000 PCE
Chi² test

PCE / NCE RATIO
Mean +/- SD
* except for positive control: 24h after unique treatment
12.8
25.6 7 +/- 0.67 
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3.2.1.3 Colon micronucleus assay 
 
No mutagenic effect was detected with NM-400, -402 and NRCWE-006 in the colon (Tables 20 to 23).  
 
Table 20: Micronucleus test on colon with NM-400. NS = non-significant at the threshold of p=0.05; 
SD = standard deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 21: Micronucleus test on colon with NM-401. NS = non-significant at the threshold of p=0.05;  
SD = standard deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLING TIME
(3-6 H after TEST ITEM
last treatment*)
DOSES in
mg/kg/day (x3)
0.05% RSA 0 3.67 +/- 2.36 1.17 +/- 0.58 15.17 +/- 4.31
DMH
POSITIVE 10 mL/kg 12.00 +/- 4.50 44.91 <0.001 11.50 +/- 2.18 85.20 <0.001 8.33 +/- 2.25 20.27 <0.001
30 mg/kg/day (x1)
4.50 +/- 1.80 0.86 N.S. 1.67 +/- 0.58 0.88 N.S. 7.83 +/- 5.86 23.84 <0.001
NM 400 4.33 +/- 1.04 0.56 N.S. 2.00 +/- 0.50 2.20 N.S. 6.50 +/- 1.50 35.30 <0.001
3.83 +/- 1.26 0.04 N.S. 2.33 +/- 0.58 3.90 <0.05 7.50 +/- 3.12 26.43 <0.001
N.S.: Non-significant at the threshold of p=0.05
PCE: Polychromatic erythocytes
NCE: Normochromatic erythocytes
SD: Standard Deviation
APOPTOSIS FOR 1000 cells
Chi² test
Mean +/- SD
 pp
12.8
Mean +/- SD
MICRONUCLEI FOR 1000 cells
Chi² test

3.2
6.4
MITOSIS FOR 1000 cells
Chi² test
Mean +/- SD
 p
* except for positive control: 24h after unique treatment
SAMPLING TIME
(3-6 H after TEST ITEM
last treatment*)
DOSES in
mg/kg/day (x3)
0.05% RSA 0 2.30 +/- 1.48 1.00 +/- 0.61 9.80 +/- 5.51
DMH
POSITIVE 10 mL/kg 7.50 +/- 4.87 35.35 <0.001 8.90 +/- 5.24 74.84 <0.001 8.40 +/- 5.16 0.02 N.S.
30 mg/kg/day (x1)
1.70 +/- 0.57 2.77 N.S. 0.60 +/- 0.65 2.11 N.S. 5.20 +/- 1.82 26.73 <0.001
NM 401 1.80 +/- 0.57 2.26 N.S. 0.60 +/- 0.42 2.11 N.S. 9.60 +/- 3.40 2.93 N.S.
3.30 +/- 1.10 0.26 N.S. 1.20 +/- 0.76 0.01 N.S. 6.40 +/- 2.46 17.05 <0.001
N.S.: Non-significant at the threshold of p=0.05
PCE: Polychromatic erythocytes
NCE: Normochromatic erythocytes
SD: Standard Deviation
mitosis FOR 1000 cells
Chi² test
Mean +/- SD
 p
* except for positive control: 24h after unique treatment
12.8
25.6
51.2
p
Mean +/- SD
MICRONUCLEI FOR 1000 cells
Chi² test

APOPTOSIS FOR 1000 cells
Chi² test
Mean +/- SD
 p
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Table 22: Micronucleus test on colon with NM-402. NS = non-significant at the threshold of p=0.05;  
SD = standard deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 23: Micronucleus test on colon with NRCWE-006. NS = non-significant at the threshold of 
p=0.05;  
SD = standard deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General conclusions 
 
In the assays performed by instillation, statistically significant effects were noted with: 
- NM-400 in the Kidney in the absence of FpG, 
- NM-401 in the Spleen both in the absence and the presence of FpG. Moreover, it 
induced a statistically significant effect in the Kidney in the presence of FpG and in the 
SAMPLING TIME
(3-6 H after TEST ITEM
last treatment*)
DOSES in
mg/kg/day (x3)
0.05% RSA 0 10.75 +/- 1.32 4.00 +/- 1.58 9.75 +/- 1.04
DMH
POSITIVE 10 mL/kg 33.00 +/- 7.74 71.72 <0.001 25.90 +/- 8.14 118.85 <0.001 14.80 +/- 3.55 2.26 N.S.
30 mg/kg/day (x1)
10.70 +/- 3.51 2.83 N.S. 6.10 +/- 3.05 9.92 <0.01 9.00 +/- 4.24 4.38 <0.05
NM 402 8.80 +/- 2.20 8.90 <0.01 6.40 +/- 2.46 6.04 <0.05 8.00 +/- 2.69 7.98 <0.01
10.60 +/- 2.22 3.05 N.S. 5.30 +/- 0.97 29.82 <0.001 12.90 +/- 4.55 0.18 N.S.
N.S.: Non-significant at the threshold of p=0.05
PCE: Polychromatic erythocytes
NCE: Normochromatic erythocytes
SD: Standard Deviation
MITOSIS FOR 1000 cells
Chi² test
Mean +/- SD
 p
* except for positive control: 24h after unique treatment
12.6
25.8
51.2
Mean +/- SD
MICRONUCLEI FOR 1000 cells
Chi² test
  pp
APOPTOSIS FOR 1000 cells
Chi² test
Mean +/- SD
SAMPLING TIME
(3-6 H after TEST ITEM
last treatment*)
DOSES in
mg/kg/day (x3)
0.05% RSA 0 2.00 +/- 2.06 2.80 +/- 1.15 15.10 +/- 7.72
DMH
POSITIVE 10 mL/kg 13.00 +/- 0.79 81.28 <0.001 22.20 +/- 5.30 152.45 <0.001 6.20 +/- 1.15 37.59 <0.001
30 mg/kg/day (x1)
1.60 +/- 1.02 0.45 N.S. 1.30 +/- 1.20 5.50 <0.05 8.60 +/- 3.66 18.04 <0.001
Mitsui 2.30 +/- 0.91 0.21 N.S. 1.40 +/- 1.08 4.68 <0.05 8.60 +/- 4.38 18.04 <0.001
2.40 +/- 1.02 0.36 N.S. 3.00 +/- 0.35 0.07 N.S. 16.60 +/- 6.17 0.72 N.S.
mitosis FOR 1000 cells
Chi² test
Mean +/- SD
 p
* except for positive control: 24h after unique treatment
12.6
25.8
51.2
Mean +/- SD
MICRONUCLEI FOR 1000 cells
Chi² test
 p
APOPTOSIS FOR 1000 cells
Chi² test
Mean +/- SD
 p
NRCWE 
006 
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BAL in the absence of FpG. It also induced a statistically significant increase in the 
percentage of DNA in tail in the lung at low dose in absence of FpG that was not 
confirmed in a further experiment with decreased doses. 
- NM-402 in the Kidney in the presence of FpG. 
- NRCWE-006 in the Kidney, the Lung and in the BAL in the absence of FpG. 
 
In the assays performed by the oral route, statistically significant increases in the percentage of DNA 
in tail were observed with:  
- NM-400 in the Kidney in the presence of FpG,  
- NM-401 in the Liver and the Kidney in the absence of FpG. 
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In brief for CNT 
- Dose ranges: 
Instillation: 0.4, 0.2 and 0.1 mg/kg (x3) except for NM-402 (1.6, 0.8 and 0.4 mg/kg (x3)) 
 An assay was also done only with NM401 at lower doses: 0.05, 0.1 and 0.2 mg/kg (x3) 
Gavage: 51.2, 25.6 and 12.8 mg/kg (x 3) except for NM-400 (12.8, 6.4, 3.2 mg/kg (x3)) 
 
- Comet assay: 
Some genotoxicity induced in various organs  
After gavage NM-401 in liver and kidney  
After instillation, depending on the MN, in kidney, spleen, lung and BAL 
- Micronucleus assay: 
-  Bone marrow: 
No mutagenicity irrespective of the route of administration 
-  Colon: 
 No mutagenicity with NM-400, -401, -402 and NRCWE-006. 
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Outcome tables 
 
The outcome tables present an overview of the statistic analysis of all the results provided within the 
WP. The statistics were performed as described in the Material & Methods with the chi-square test 
for the micronucleus assays (both colon and bone marrow) and the non-parametric Kruskall-Wallis 
test for the comet assay. 
 
The following  
 
+++, POSITIVE - Significant dose-dependent increase, ≥2 significant doses. 
++, POSITIVE - Significant dose-dependent increase, high dose significant.   
+, POSITIVE - No significant dose-dependent increase,  ≥2 significant doses.    
(+), EQUIVOCAL - No significant dose-dependent increase, 1 significant dose.    
-, NEGATIVE;  
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Table 24. Outcome of the in vivo micronucleus assay after gavage or instillation with Nanogenotox 
MNs.  
 
Route Gavage Instillation Intravenous 
Organ of 
origin 
Bone 
marrow 
Colon 
Bone 
marrow 
Bone 
marrow 
Bone 
marrow 
(LacZ mice) 
TiO2          
NM-101 ND ND  ND  
NM-102 - * - ND - 
NM-103 - * - - ND 
NM-104 - * - - ND 
NM-105 - * - ND ND 
SAS      
NM-200 - - - ND ND 
NM-201 - - - ND ND 
NM-202 - (+) - ND ND 
NM-203 - (+) - (+) ND 
MWCNT      
NM-400 - - - ND ND 
NM-401 - - - ND ND 
NM-402 - - - ND ND 
NRCWE-006 - - - ND ND 
 
ND, NO DATA (not performed); * = technical problem 
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Table 25. Outcome of the in vivo comet assay after instillation with Nanogenotox NMs.  
 
Tissue BAL fluid Lung 
Blood 
(not 
compulsory) 
Bone 
marrow 
 
Spleen 
Liver Kidney 
TiO2             
NM-101 ++ - ND ND - - - 
NM-102 - - ND ND - (+) - 
NM-103 - - ND ND - (+) - 
NM-104 - - ND ND - - - 
NM-105 ++ - ND ND - - - 
SAS        
NM-200 - - - - - - - 
NM-201 - - - - - - - 
NM-202 - - - - - - - 
NM-203 - - - - - - - 
MWCNT        
NM-400 ND ** ND ND ID - ++ 
NM-401 - (+) ND ND (+) - - 
NM-402 - - ND ND - - - 
NRCWE-006 (+) (+) ND ND - - (+) 
 
ND, NO DATA (not performed). 
ID: Invalidated data 
** Technical problem: no cells were analysable 
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Table 26. Outcome of the in vivo comet assay after gavage with Nanogenotox MNs.  
 
Tissue Intestine Colon 
Blood 
(not 
compulsory) 
Bone 
marrow 
 
Spleen 
Liver Kidney 
TiO2              
NM-102 - ++ - - +++ - - 
NM-103 ++ - - - (+) - - 
NM-104 - - - ++ +++ - - 
NM-105 - ++ - - + - - 
SAS        
NM-200 - - - - - - - 
NM-201 - - - - - - - 
NM-202 - - - - - - - 
NM-203 - - - - - - - 
MWCNT        
NM-400 ND - ND ND - - - 
NM-401 ND - ND ND - (+) (+) 
NM-402 ND ID ND ND - - - 
NRCWE-006 ND - ND ND - - - 
 
ND, NO DATA (not performed). 
ID: Invalidated data 
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Table 27. Outcome of the in vivo comet assay for oxidative DNA damage (FpG) after instillation 
with Nanogenotox MNs.  
 
Tissue BAL fluid Lung 
Blood 
(not 
compulsory) 
Bone 
marrow 
 
Spleen 
Liver Kidney 
TiO2              
NM-102 ND ND ND ND ND ND ND 
NM-103 ND ND ND ND ND ND ND 
NM-104 ND ND ND ND ND ND ND 
NM-105 ND ND ND ND ND ND ND 
SAS        
NM-200 - - - - (+)* - - 
NM-201 - - - - - - - 
NM-202 - - - - - - - 
NM-203 - - - - - - - 
MWCNT        
NM-400 ND ** ND ND ID - - 
NM-401 - - ND ND (+) - + 
NM-402 - - ND ND - - + 
NRCWE-006 ID ID ND ND - - ID 
*intermediate dose significantly different from control 
 
ND, NO DATA (not performed). 
ID: Invalidated data 
** Technical problem: no cells were analysable 
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Table 28. Outcome of the in vivo comet assay for oxidative DNA damage (FpG) after gavage with 
Nanogenotox MNs. 
 
Tissue Intestine Colon 
Blood 
(not 
compulsory) 
Bone 
marrow 
 
Spleen 
Liver Kidney 
TiO2             
NM-102 - - ND ND ND ND ND 
NM-103 - - ND ND ND ND ND 
NM-104 - - ND ND ND ND ND 
NM-105 - - ND ND ND ND ND 
SAS        
NM-200 - - - - - - - 
NM-201 - - - - - - - 
NM-202 - - - - - - - 
NM-203 - - - - - - - 
MWCNT        
NM-400 ND - ND ND - - (+) 
NM-401 ND ID ND ND - - ID 
NM-402 ND ID ND ND ID - ID 
NRCWE-006 ND - ND ND - - - 
 
ND, NO DATA (not performed) 
 
ID: Invalidated data 
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Data correlations 
 
The correlations between in vivo and in vitro responses as well as between in vivo and physic-chem 
properties could not be done during the framework as some results from the in vivo workpackage are 
still expected and numerous data were only reported by January and February 2013. Some 
investigations on those correlations are planned in the upcoming months. 
 
Conclusions 
 
With the comet assay, the responses were largely negative in the tested organs for most of the 
investigated MNs. When positive results were obtained, in most cases, no dose response relationship 
could be established which makes it difficult to conclude on the in vivo genotoxicity of the MNs 
tested.  
The WP6 results herein presented show that no chromosome damage was observed in bone marrow 
after gavage, intratracheal and intravenous administrations, irrespective of the MN. As generally a 
low bioavailability for internal organs after gavage was observed in the toxicokinetics workpackage 
(WP7), the MNs are likely not to have reached the bone marrow. Therefore, the bone marrow 
micronucleus test may not be appropriate for MN in vivo genotoxicity detection, unless some uptake 
in this tissue could be demonstrated. Some mutagenicity was observed in colon with the 
micronucleus assay for two SAS MNs but only at the lowest dose without a dose-response. However, 
no micronucleus induction was reported with three CNT. The results from TiO2 and one CNT are still 
expected. 
Apparently, within the same family, the toxic effect may vary according to the MN (genotoxicity but 
also toxic effects). The genotoxic effects observed in few organs during this WP need however to be 
confirmed. Moreover, some low dose effects were reported and additional investigations would be 
required to explain these results. 
A critical analysis of the in vivo genotoxicity of MNs must be carried out as soon as the last results will 
be provided. Correlations with in vitro and physic-chemical properties are also planned. 
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Recommendations 
 
We highlighted during this workpackage some intra and inter laboratory variabilities as presented in 
Figure 46 for the comet assay on liver. However, it must also be outlined that most of the labs 
involved in the comet assay showed a weak variability of the results obtained with controls (negative 
and positive) considering that neither the isolation nor the protocol of migration were harmonised 
before running the comet assay. 
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Figure 46: Variability of comet assay responses in liver for negative (vehicle) and positive (MMS) 
controls among the different laboratories involved in the WP. Each point is the median of one 
animal. 
Unfortunately, as this project was innovative in the protocol used (3 administrations) and in the 
number of organs to be investigated (at least 5 per animal), the laboratories did not have historical 
data available or only on few specific organs (mostly liver). Moreover, the comet assay and the colon 
micronucleus assay do not have OECD guidelines. Although some recommendation papers exist for 
the in vivo comet assay (Tice et al 2000, Hartmann et al 2003, EFSA 2012), the criteria of acceptability 
are not well established yet. 
The bone marrow micronucleus test may not be appropriate for MN in vivo genotoxicity detection 
since the uptake in this tissue has not been confirmed. Investigating sites of contact (lung and gut) 
for genotoxic effect of MNs should be also recommended. Complementary tests to the OECD 474 
guideline including comet assay, colon or lung micronucleus assay and lacZ mutation assay could be 
promising tools that need to be pushed through the validation process. 
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